Note 1. Basis of presentation and summary of significant accounting policies
\n\u00a0
\nThe accompanying unaudited\u00a0condensed interim consolidated financial statements (the \u201cFinancial Statements\u201d) reflect the accounts of the Company for the quarterly period ended August 31, 2024. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (\u201cU.S. GAAP\u201d) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (\u201cSEC\u201d) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the \u201cAnnual Financial Statements\u201d) included in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended\u00a0 May 31, 2024\u00a0(the \u201cAnnual Report\u201d). These\u00a0Financial Statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full fiscal year.\u00a0
\n\u00a0
\nThese Financial Statements have been prepared on a\u00a0going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company\u2019s accounting policies.
\n\u00a0
\nAll amounts in the Financial Statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.
\n\u00a0
\nCertain items of the comparative figures have been changed to conform to the presentation adopted in the current period.\u00a0
\n\u00a0
\n\n
Basis of consolidation
\u00a0
Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\u00a0
\n\n
Convertible notes receivable
\u00a0
Convertible notes receivable\u00a0includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).
\u00a0
\n \n\n
Earnings (loss) per share
\u00a0
Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\u00a0
In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three\u00a0months ended\u00a0 August 31, 2024 and\u00a0 August 31, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 23,411,577 and 21,202,933 common shares from RSUs, 3,359,144 and 6,325,348 common shares from share options, 6,210,000 and 7,847,219 common shares for warrants and 64,971,746 and 77,819,141 common shares for convertible debentures, respectively.
\u00a0
\n\n
New accounting pronouncements not yet adopted\u00a0
\u00a0
In August 2023, the Financial Accounting Standards Board (\"FASB\") issued Accounting Standards Update (\"ASU\") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.
\u00a0
In October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\u00a0
In\u00a0 December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company\u00a0beginning with the fiscal year ended\u00a0 June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\u00a0
New accounting pronouncements recently adopted
\u00a0
In November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments\u2019 significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning with the fiscal year ended May 31, 2025 and will be disclosed retrospectively\u00a0in the Annual Report on Form 10-K.\u00a0
\u00a0
On March 21, 2024,\u00a0the FASB issued ASU\u00a02024-01,\u00a0Compensation\u2014Stock Compensation (Topic\u00a0718): Scope Application of Profits Interest and Similar Awards, which adds illustrative examples that demonstrate how the scoping guidance in ASC\u00a0718-10-15-3\u00a0applies to profits interest or similar awards. The Company adopted ASU\u00a02024-01\u00a0beginning with the fiscal year ended\u00a0 June 1, 2024\u00a0with no material impacts.
\n \n\u00a0
\n \n \n "}]},{"name":"rpt:f-521","factDimensions":{"xbrl:concept":"us-gaap:BasisOfAccountingPolicyPolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Basis of consolidation
\u00a0
Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.
\u00a0
"}]},{"name":"rpt:f-522","factDimensions":{"xbrl:concept":"us-gaap:FinanceLoansAndLeasesReceivablePolicy","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Convertible notes receivable
\u00a0
Convertible notes receivable\u00a0includes various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the consolidated statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of loss and the remaining amount is recorded in other comprehensive income (loss).
\u00a0
\n "}]},{"name":"rpt:f-523","factDimensions":{"xbrl:concept":"us-gaap:EarningsPerSharePolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"Earnings (loss) per share
\u00a0
Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the\u00a0share lending\u00a0arrangement entered into in conjunction with the TLRY\u00a027 Notes, see Note\u00a013\u00a0(Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share\u00a0because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.\u00a0
\u00a0
In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three\u00a0months ended\u00a0 August 31, 2024 and\u00a0 August 31, 2023, the dilutive potential common share equivalents outstanding consisted of the following: 23,411,577 and 21,202,933 common shares from RSUs, 3,359,144 and 6,325,348 common shares from share options, 6,210,000 and 7,847,219 common shares for warrants and 64,971,746 and 77,819,141 common shares for convertible debentures, respectively.
\u00a0
"}]},{"name":"rpt:f-524","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"23411577"}]},{"name":"rpt:f-525","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:RestrictedStockUnitsRSUMember"},"factValues":[{"value":"21202933"}]},{"name":"rpt:f-526","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"3359144"}]},{"name":"rpt:f-527","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"us-gaap:EmployeeStockOptionMember"},"factValues":[{"value":"6325348"}]},{"name":"rpt:f-528","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:WarrantsMember"},"factValues":[{"value":"6210000"}]},{"name":"rpt:f-529","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:WarrantsMember"},"factValues":[{"value":"7847219"}]},{"name":"rpt:f-530","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"64971746"}]},{"name":"rpt:f-531","factDimensions":{"xbrl:concept":"us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"77819141"}]},{"name":"rpt:f-532","factDimensions":{"xbrl:concept":"us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"New accounting pronouncements not yet adopted\u00a0
\u00a0
In August 2023, the Financial Accounting Standards Board (\"FASB\") issued Accounting Standards Update (\"ASU\") 2023-05, Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (\u201cASU 2023-05\u201d), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.
\u00a0
In October\u00a02023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC\u2019s Disclosure Update and Simplification Initiative,\u00a0which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the \u201cCodification\u201d). The effective date for each amendment will be the date on which the SEC\u2019s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity.\u00a0The Company is currently evaluating the effect of adopting this ASU.\u00a0
\u00a0
In\u00a0 December 2023,\u00a0the FASB issued ASU\u00a02023-09,\u00a0Income Taxes (Topic\u00a0740)\u00a0Improvements to Income Tax Disclosures,\u00a0which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU\u00a02023-09\u00a0is effective for the Company\u00a0beginning with the fiscal year ended\u00a0 June 1, 2025.\u00a0The Company is currently evaluating the effect of adopting this ASU.
\u00a0
New accounting pronouncements recently adopted
\u00a0
In November\u00a02023, the FASB issued ASU 2023-07,\u00a0Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures,\u00a0which requires public entities to disclose information about their reportable segments\u2019 significant expenses on an interim and annual basis.\u00a0ASU 2023-07 is effective for the Company beginning with the fiscal year ended May 31, 2025 and will be disclosed retrospectively\u00a0in the Annual Report on Form 10-K.\u00a0
\u00a0
On March 21, 2024,\u00a0the FASB issued ASU\u00a02024-01,\u00a0Compensation\u2014Stock Compensation (Topic\u00a0718): Scope Application of Profits Interest and Similar Awards, which adds illustrative examples that demonstrate how the scoping guidance in ASC\u00a0718-10-15-3\u00a0applies to profits interest or similar awards. The Company adopted ASU\u00a02024-01\u00a0beginning with the fiscal year ended\u00a0 June 1, 2024\u00a0with no material impacts.
"}]},{"name":"rpt:f-533","factDimensions":{"xbrl:concept":"us-gaap:InventoryDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 2. Inventory
\n\u00a0
\nInventory consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nAugust 31, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Beverage alcohol inventory | \n \u00a0 | \n\u00a0 | \n58,784 | \n\u00a0 | \n\u00a0 | \n$ | \n52,831 | \n\u00a0 | \n
| Plants | \n \u00a0 | \n\u00a0 | \n16,333 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n13,828 | \n\u00a0 | \n
| Dried cannabis | \n \u00a0 | \n\u00a0 | \n107,290 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n108,721 | \n\u00a0 | \n
| Cannabis derivatives | \n \u00a0 | \n\u00a0 | \n7,306 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,504 | \n\u00a0 | \n
| Cannabis vapes | \n \u00a0 | \n\u00a0 | \n4,858 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,132 | \n\u00a0 | \n
| Packaging and other inventory items | \n \u00a0 | \n\u00a0 | \n20,270 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n22,115 | \n\u00a0 | \n
| Distribution inventory | \n \u00a0 | \n\u00a0 | \n38,202 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n35,645 | \n\u00a0 | \n
| Wellness inventory | \n \u00a0 | \n\u00a0 | \n11,252 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,311 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n264,295 | \n\u00a0 | \n\u00a0 | \n$ | \n252,087 | \n\u00a0 | \n
\u00a0\u00a0
\n "}]},{"name":"rpt:f-534","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfInventoryCurrentTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nAugust 31, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Beverage alcohol inventory | \n \u00a0 | \n\u00a0 | \n58,784 | \n\u00a0 | \n\u00a0 | \n$ | \n52,831 | \n\u00a0 | \n
| Plants | \n \u00a0 | \n\u00a0 | \n16,333 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n13,828 | \n\u00a0 | \n
| Dried cannabis | \n \u00a0 | \n\u00a0 | \n107,290 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n108,721 | \n\u00a0 | \n
| Cannabis derivatives | \n \u00a0 | \n\u00a0 | \n7,306 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,504 | \n\u00a0 | \n
| Cannabis vapes | \n \u00a0 | \n\u00a0 | \n4,858 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,132 | \n\u00a0 | \n
| Packaging and other inventory items | \n \u00a0 | \n\u00a0 | \n20,270 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n22,115 | \n\u00a0 | \n
| Distribution inventory | \n \u00a0 | \n\u00a0 | \n38,202 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n35,645 | \n\u00a0 | \n
| Wellness inventory | \n \u00a0 | \n\u00a0 | \n11,252 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,311 | \n\u00a0 | \n
| Total | \n \u00a0 | \n$ | \n264,295 | \n\u00a0 | \n\u00a0 | \n$ | \n252,087 | \n\u00a0 | \n
Note 3. Capital assets
\n\u00a0
\nCapital assets consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \nAugust 31, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n45,165 | \n\u00a0 | \n\u00a0 | \n$ | \n45,577 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n375,345 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n369,630 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n262,876 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n258,532 | \n\u00a0 | \n
| Leasehold improvements | \n \u00a0 | \n\u00a0 | \n19,463 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,377 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n43,429 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n43,993 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n12,516 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,713 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n758,794 | \n\u00a0 | \n\u00a0 | \n$ | \n747,822 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(203,658 | \n) | \n\u00a0 | \n\u00a0 | \n(189,575 | \n) | \n
| Total | \n \u00a0 | \n$ | \n555,136 | \n\u00a0 | \n\u00a0 | \n$ | \n558,247 | \n\u00a0 | \n
\u00a0 \u00a0\u00a0
\nAssets held for sale\u00a0consisted of the following:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n August 31, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n970 | \n\u00a0 | \n\u00a0 | \n$ | \n954 | \n\u00a0 | \n
| Production facility | \n \u00a0 | \n\u00a0 | \n25,010 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,682 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n6,556 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,438 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n32,536 | \n\u00a0 | \n\u00a0 | \n$ | \n32,074 | \n\u00a0 | \n
\u00a0
\nDuring the fiscal year ended\u00a0 May 31, 2024,\u00a0the Company classified the following assets from its Cannabis reporting segment as held for sale, including its\u00a0Quebec cultivation facility, the Fort Collins, CO partially vacant warehouse facility, and the Broken Coast\u00a0former cultivation facility located in Duncan, B.C.. Following an\u00a0assessment of facility capacity utilization, it was determined that these facilities would be exited and held for sale.\u00a0It is expected that the sale of these assets\u00a0will be completed within\u00a0twelve\u00a0months from the period in which they were classified as held for sale. Assets held for sale are\u00a0measured at the lower of carrying amount and their fair value less costs to sell, and are\u00a0no\u00a0longer depreciated. Disposition of assets held for sale are recorded in the consolidated statement of net loss and comprehensive loss, within the line, \u201cNon-operating income (expense), net\u201d.\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-554","factDimensions":{"xbrl:concept":"us-gaap:PropertyPlantAndEquipmentTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \nAugust 31, | \n\u00a0 | \n\u00a0 | \nMay 31, | \n\u00a0 | \n||
| \u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n\u00a0 | \n2024 | \n\u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n45,165 | \n\u00a0 | \n\u00a0 | \n$ | \n45,577 | \n\u00a0 | \n
| Production facilities | \n \u00a0 | \n\u00a0 | \n375,345 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n369,630 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n262,876 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n258,532 | \n\u00a0 | \n
| Leasehold improvements | \n \u00a0 | \n\u00a0 | \n19,463 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n19,377 | \n\u00a0 | \n
| Finance lease, right-of-use assets | \n \u00a0 | \n\u00a0 | \n43,429 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n43,993 | \n\u00a0 | \n
| Construction in progress | \n \u00a0 | \n\u00a0 | \n12,516 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n10,713 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n758,794 | \n\u00a0 | \n\u00a0 | \n$ | \n747,822 | \n\u00a0 | \n
| Less: accumulated amortization | \n \u00a0 | \n\u00a0 | \n(203,658 | \n) | \n\u00a0 | \n\u00a0 | \n(189,575 | \n) | \n
| Total | \n \u00a0 | \n$ | \n555,136 | \n\u00a0 | \n\u00a0 | \n$ | \n558,247 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n August 31, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Land | \n \u00a0 | \n$ | \n970 | \n\u00a0 | \n\u00a0 | \n$ | \n954 | \n\u00a0 | \n
| Production facility | \n \u00a0 | \n\u00a0 | \n25,010 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n24,682 | \n\u00a0 | \n
| Equipment | \n \u00a0 | \n\u00a0 | \n6,556 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n6,438 | \n\u00a0 | \n
| \u00a0 | \n\u00a0 | \n$ | \n32,536 | \n\u00a0 | \n\u00a0 | \n$ | \n32,074 | \n\u00a0 | \n
\u00a0Note 4. Leases
\n\u00a0
\nThe table below presents the lease-related assets and liabilities recorded on the balance sheet.
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 43,429 | \u00a0 | \u00a0 | $ | 43,993 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 17,176 | \u00a0 | \u00a0 | \u00a0 | 16,101 | \u00a0 |
| Total right-of-use asset | \u00a0 | $ | 60,605 | \u00a0 | \u00a0 | $ | 60,094 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,116 | \u00a0 | \u00a0 | $ | 1,092 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 4,524 | \u00a0 | \u00a0 | \u00a0 | 3,999 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 43,737 | \u00a0 | \u00a0 | \u00a0 | 43,948 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 16,920 | \u00a0 | \u00a0 | \u00a0 | 16,474 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 66,297 | \u00a0 | \u00a0 | $ | 65,513 | \u00a0 |
\u00a0
\nThe following table presents the future undiscounted payments associated with lease liabilities as of August 31, 2024:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n Operating | \n \u00a0 | \n\u00a0 | \n Finance | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n||
| 2025 | \n \u00a0 | \n$ | \n4,775 | \n\u00a0 | \n\u00a0 | \n$ | \n3,299 | \n\u00a0 | \n
| 2026 | \n \u00a0 | \n\u00a0 | \n6,089 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| 2027 | \n \u00a0 | \n\u00a0 | \n5,439 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| 2028 | \n \u00a0 | \n\u00a0 | \n4,540 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| Thereafter | \n \u00a0 | \n\u00a0 | \n6,139 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n78,781 | \n\u00a0 | \n
| Total minimum lease payments | \n \u00a0 | \n$ | \n26,982 | \n\u00a0 | \n\u00a0 | \n$ | \n95,274 | \n\u00a0 | \n
| Imputed interest | \n \u00a0 | \n\u00a0 | \n(5,538 | \n) | \n\u00a0 | \n\u00a0 | \n(50,421 | \n) | \n
| Obligations recognized | \n \u00a0 | \n$ | \n21,444 | \n\u00a0 | \n\u00a0 | \n$ | \n44,853 | \n\u00a0 | \n
\u00a0
\n "}]},{"name":"rpt:f-583","factDimensions":{"xbrl:concept":"tlry:LeaseRelatedAssetsAndLiabilitiesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | Classification on Balance Sheet | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease, right-of-use assets | Capital assets | \u00a0 | $ | 43,429 | \u00a0 | \u00a0 | $ | 43,993 | \u00a0 |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | \u00a0 | \u00a0 | 17,176 | \u00a0 | \u00a0 | \u00a0 | 16,101 | \u00a0 |
| Total right-of-use asset | \u00a0 | $ | 60,605 | \u00a0 | \u00a0 | $ | 60,094 | \u00a0 | |
| Liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current portion of finance lease liabilities |
| \u00a0 | $ | 1,116 | \u00a0 | \u00a0 | $ | 1,092 | \u00a0 |
| Current portion of operating lease liabilities |
| \u00a0 | \u00a0 | 4,524 | \u00a0 | \u00a0 | \u00a0 | 3,999 | \u00a0 |
| Non-current: | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities |
| \u00a0 | \u00a0 | 43,737 | \u00a0 | \u00a0 | \u00a0 | 43,948 | \u00a0 |
| Operating lease liabilities |
| \u00a0 | \u00a0 | 16,920 | \u00a0 | \u00a0 | \u00a0 | 16,474 | \u00a0 |
| Total lease liabilities | \u00a0 | $ | 66,297 | \u00a0 | \u00a0 | $ | 65,513 | \u00a0 |
| \u00a0 | \n\u00a0 | \n Operating | \n \u00a0 | \n\u00a0 | \n Finance | \n \u00a0 | \n||
| \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n\u00a0 | \n leases | \n \u00a0 | \n||
| 2025 | \n \u00a0 | \n$ | \n4,775 | \n\u00a0 | \n\u00a0 | \n$ | \n3,299 | \n\u00a0 | \n
| 2026 | \n \u00a0 | \n\u00a0 | \n6,089 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| 2027 | \n \u00a0 | \n\u00a0 | \n5,439 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| 2028 | \n \u00a0 | \n\u00a0 | \n4,540 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,398 | \n\u00a0 | \n
| Thereafter | \n \u00a0 | \n\u00a0 | \n6,139 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n78,781 | \n\u00a0 | \n
| Total minimum lease payments | \n \u00a0 | \n$ | \n26,982 | \n\u00a0 | \n\u00a0 | \n$ | \n95,274 | \n\u00a0 | \n
| Imputed interest | \n \u00a0 | \n\u00a0 | \n(5,538 | \n) | \n\u00a0 | \n\u00a0 | \n(50,421 | \n) | \n
| Obligations recognized | \n \u00a0 | \n$ | \n21,444 | \n\u00a0 | \n\u00a0 | \n$ | \n44,853 | \n\u00a0 | \n
Note 5. Intangible Assets
\n\u00a0
\nIntangible assets consisted of the following items:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Customer relationships & distribution channel | \u00a0 | $ | 609,728 | \u00a0 | \u00a0 | $ | 603,939 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 371,507 | \u00a0 | \u00a0 | \u00a0 | 368,057 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,441 | \u00a0 | \u00a0 | \u00a0 | 12,403 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 616,721 | \u00a0 | \u00a0 | \u00a0 | 608,672 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,610,397 | \u00a0 | \u00a0 | $ | 1,593,071 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (285,785 | ) | \u00a0 | \u00a0 | (261,758 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 908,768 | \u00a0 | \u00a0 | $ | 915,469 | \u00a0 |
\u00a0
\nIncluded in Licenses, permits & applications was\u00a0$185,636\u00a0of indefinite-lived intangible assets as of August 31, 2024, compared to $182,851\u00a0as of May 31, 2024.
\n\u00a0
\nExpected future amortization expense for intangible assets as of\u00a0 August 31, 2024\u00a0is\u00a0as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2025 (remaining nine months) | \u00a0 | $ | 55,822 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 369,590 | \u00a0 |
| Total | \u00a0 | $ | 723,132 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-618","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Customer relationships & distribution channel | \u00a0 | $ | 609,728 | \u00a0 | \u00a0 | $ | 603,939 | \u00a0 |
| Licenses, permits & applications | \u00a0 | \u00a0 | 371,507 | \u00a0 | \u00a0 | \u00a0 | 368,057 | \u00a0 |
| Non-compete agreements | \u00a0 | \u00a0 | 12,441 | \u00a0 | \u00a0 | \u00a0 | 12,403 | \u00a0 |
| Intellectual property, trademarks, knowhow & brands | \u00a0 | \u00a0 | 616,721 | \u00a0 | \u00a0 | \u00a0 | 608,672 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | 1,610,397 | \u00a0 | \u00a0 | $ | 1,593,071 | \u00a0 |
| Less: accumulated amortization | \u00a0 | \u00a0 | (285,785 | ) | \u00a0 | \u00a0 | (261,758 | ) |
| Less: impairments | \u00a0 | \u00a0 | (415,844 | ) | \u00a0 | \u00a0 | (415,844 | ) |
| Total | \u00a0 | $ | 908,768 | \u00a0 | \u00a0 | $ | 915,469 | \u00a0 |
| \u00a0 | \u00a0 | Amortization | \u00a0 | |
| 2025 (remaining nine months) | \u00a0 | $ | 55,822 | \u00a0 |
| 2026 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2027 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2028 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| 2029 | \u00a0 | \u00a0 | 74,430 | \u00a0 |
| Thereafter | \u00a0 | \u00a0 | 369,590 | \u00a0 |
| Total | \u00a0 | $ | 723,132 | \u00a0 |
Note 6. Goodwill
\n\u00a0
\nThe following table shows the carrying amount of goodwill by reporting units:
\n\u00a0
\n \n| \u00a0 | \n\u00a0 | \n August 31, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| Reporting Unit | \n \u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Cannabis | \n \u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n\u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n
| Distribution | \n \u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n
| Beverage alcohol | \n \u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n
| Wellness | \n \u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n
| Effect of foreign exchange | \n \u00a0 | \n\u00a0 | \n8,746 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,916 | \n\u00a0 | \n
| Impairments | \n \u00a0 | \n\u00a0 | \n(842,431 | \n) | \n\u00a0 | \n\u00a0 | \n(842,431 | \n) | \n
| Total | \n \u00a0 | \n$ | \n2,009,714 | \n\u00a0 | \n\u00a0 | \n$ | \n2,008,884 | \n\u00a0 | \n
\u00a0
\n \n \n "}]},{"name":"rpt:f-646","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfGoodwillTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \n\u00a0 | \n August 31, | \n \u00a0 | \n\u00a0 | \n May 31, | \n \u00a0 | \n||
| Reporting Unit | \n \u00a0 | \n 2024 | \n \u00a0 | \n\u00a0 | \n 2024 | \n \u00a0 | \n||
| Cannabis | \n \u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n\u00a0 | \n$ | \n2,640,669 | \n\u00a0 | \n
| Distribution | \n \u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n4,458 | \n\u00a0 | \n
| Beverage alcohol | \n \u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n120,802 | \n\u00a0 | \n
| Wellness | \n \u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n77,470 | \n\u00a0 | \n
| Effect of foreign exchange | \n \u00a0 | \n\u00a0 | \n8,746 | \n\u00a0 | \n\u00a0 | \n\u00a0 | \n7,916 | \n\u00a0 | \n
| Impairments | \n \u00a0 | \n\u00a0 | \n(842,431 | \n) | \n\u00a0 | \n\u00a0 | \n(842,431 | \n) | \n
| Total | \n \u00a0 | \n$ | \n2,009,714 | \n\u00a0 | \n\u00a0 | \n$ | \n2,008,884 | \n\u00a0 | \n
Note 7.\u00a0Business\u00a0acquisitions
\n\u00a0\u00a0
\nAcquisition of Craft\u00a0Beverage\u00a0Business Portfolio
\n\u00a0
\nOn\u00a0\u00a0 September 29, 2023,\u00a0Tilray acquired a portfolio of craft brands, assets and businesses comprising\u00a0\u00a0beer and beverage brands from Anheuser-Busch Companies, LLC, (\"AB\") including breweries and brewpubs associated with them (the \u201cCraft\u00a0Acquisition\u201d). The acquired businesses/brands\u00a0include\u00a0Shock Top,\u00a0Breckenridge Brewery,\u00a0Blue Point Brewing Company,\u00a010\u00a0Barrel Brewing Company,\u00a0Redhook Brewery, Widmer Brothers Brewing,\u00a0Square Mile Cider Company, and HiBall Energy. The Company paid a total purchase price equivalent of $83,658\u00a0in cash, net of a working capital adjustment at closing of $1,342.\u00a0
\n\u00a0
\nThe Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value\u00a0\u00a0 may\u00a0be subject to adjustments pending completion of final valuations and post-closing adjustments.\u00a0The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the Craft Acquisition at the effective acquisition date\u00a0as follows:\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 21,493 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 76,114 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 45,496 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 151,538 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 14,706 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 67,880 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
\u00a0
\nIn the event that the Craft\u00a0Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional net\u00a0revenue of approximately and $41,000 for the three months ended August 31, 2024 and 2023, respectively, and its consolidated net loss and comprehensive net income would have increased by approximately\u00a0 and $3,000 for the three months ended August 31, 2024 and 2023, respectively. This unaudited pro forma financial information does\u00a0not\u00a0reflect the realization of any expected ongoing synergies relating to the integration of the Craft\u00a0Acquisition.
\n "}]},{"name":"rpt:f-662","factDimensions":{"xbrl:concept":"us-gaap:PaymentsToAcquireBusinessesGross","xbrl:period":"2023-09-29T00:00:00/2023-09-30T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"83658000","decimals":-3}]},{"name":"rpt:f-663","factDimensions":{"xbrl:concept":"tlry:WorkingCapitalAdjustment","xbrl:period":"2023-09-30T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:CraftBeverageBusinessAcquisitionMember"},"factValues":[{"value":"1342000","decimals":-3}]},{"name":"rpt:f-664","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Amount | \u00a0 | |
| Consideration | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash consideration | \u00a0 | $ | 83,658 | \u00a0 |
| Net assets acquired | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Current assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | \u00a0 | 77 | \u00a0 |
| Inventory | \u00a0 | \u00a0 | 21,493 | \u00a0 |
| Prepaids and other current assets | \u00a0 | \u00a0 | 573 | \u00a0 |
| Long-term assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Capital assets | \u00a0 | \u00a0 | 76,114 | \u00a0 |
| Finance lease, right-of-use assets | \u00a0 | \u00a0 | 45,496 | \u00a0 |
| Operating lease, right-of-use assets | \u00a0 | \u00a0 | 7,677 | \u00a0 |
| Other assets | \u00a0 | \u00a0 | 108 | \u00a0 |
| Total assets | \u00a0 | \u00a0 | 151,538 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Accounts payable and accrued liabilities | \u00a0 | \u00a0 | 14,706 | \u00a0 |
| Current portion of finance lease liabilities | \u00a0 | \u00a0 | 1,031 | \u00a0 |
| Current portion of operating lease liabilities | \u00a0 | \u00a0 | 1,408 | \u00a0 |
| Long - term liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Finance lease liabilities | \u00a0 | \u00a0 | 44,465 | \u00a0 |
| Operating lease liabilities | \u00a0 | \u00a0 | 6,270 | \u00a0 |
| Total liabilities | \u00a0 | \u00a0 | 67,880 | \u00a0 |
| Total net assets acquired | \u00a0 | \u00a0 | 83,658 | \u00a0 |
Note 8.\u00a0Convertible notes receivable
\n\u00a0
\nConvertible notes receivable is comprised of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| MedMen Convertible Note | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 32,000 | \u00a0 |
\u00a0
\n \n \nMedMen Convertible Note
\n\u00a0
\nOn August 31, 2021, the Company issued\u00a09,817,061 shares valued at $117,804 to acquire\u00a068% interest in Superhero Acquisition L.P. (\u201cSH Acquisition\u201d), which purchased a senior secured convertible note issued by MedMen (the \"MedMen Convertible Note\"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured Overnight Financing Rate (\"SOFR\") plus\u00a06%, with a SOFR floor of\u00a02.5% with any accrued interest being added to the outstanding principal amount. The outstanding principal amount, together with accrued interest\u00a0is to be paid on August 17, 2028, the\u00a0maturity date of the MedMen Convertible Note. SH Acquisition was also granted \u201ctop-up\u201d rights enabling it (and its limited partners) to maintain its percentage ownership (on an \u201cas-converted\u201d basis) in the event that MedMen issues equity securities.\u00a0SH Acquisition\u2019s ability to convert the MedMen Convertible Note\u00a0and exercise the Warrants is dependent upon U.S. federal legalization of cannabis or Tilray\u2019s waiver of such requirement as well as any additional regulatory approvals.\u00a0
\n\u00a0
\nDuring the year ended\u00a0 May 31, 2024,\u00a0the Company recognized an other-than-temporary change in fair value, which resulted in a non-cash expense of $42,681. The\u00a0MedMen Convertible Note was valued based upon the fair value of the\u00a0collateral assets net of disposal costs and has been reduced to reflect recent events, including the appointment of a chief restructuring officer on\u00a0\u00a0 January 23, 2024 to facilitate MedMen\u2019s anticipated recapitalization and restructuring of operations,\u00a0filing for insolvency protection\u00a0in Canada and in California and pending asset sales.\u00a0 There are no additional changes in fair value for\u00a0the\u00a0three months ended August 31, 2024.
\n\u00a0
\nThe Company\u00a0did not derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note.\u00a0In addition, since the fiscal year ended May 31, 2024, the Company has\u00a0 recognized any\u00a0interest income on the MedMen Convertible Note, nor did the Company recognize any interest income for the three months ended August 31, 2024, which would have\u00a0increased\u00a0its value.\u00a0
\n "}]},{"name":"rpt:f-684","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| MedMen Convertible Note | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total convertible notes receivable, non current portion | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 32,000 | \u00a0 |
Note 9. Long term investments
\n\u00a0
\nLong term investments consisted of the following:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Equity investments measured at fair value | \u00a0 | $ | 2,353 | \u00a0 | \u00a0 | $ | 2,359 | \u00a0 |
| Equity investments under measurement alternative | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 |
| Total | \u00a0 | $ | 7,853 | \u00a0 | \u00a0 | $ | 7,859 | \u00a0 |
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-699","factDimensions":{"xbrl:concept":"us-gaap:TradingSecuritiesAndCertainTradingAssetsTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Equity investments measured at fair value | \u00a0 | $ | 2,353 | \u00a0 | \u00a0 | $ | 2,359 | \u00a0 |
| Equity investments under measurement alternative | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 |
| Total | \u00a0 | $ | 7,853 | \u00a0 | \u00a0 | $ | 7,859 | \u00a0 |
Note 10. Bank indebtedness
\n\u00a0
\nAphria Inc., a subsidiary of the Company,\u00a0has an operating line of credit in the amount of which bears interest at the lender\u2019s prime rate plus 75 basis points. As of August 31, 2024, the Company has drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located\u00a0at 265 Talbot St. West, Leamington, Ontario.
\n\u00a0
\nCC Pharma GmbH, a subsidiary of the Company, has \u00a0operating lines of credit in the amounts of\u00a0\u00a0and\u00a0\u00a0These lines\u00a0bear interest at\u00a0Euro Short-Term Rate (\"ESTR\") plus 2.50% and Euro Interbank Offered Rate (\"EURIBOR\") plus 4.00%, respectively. As of August 31, 2024, a total of ($8,134) was drawn down from the total available credit of\u00a0\u00a0The operating line\u00a0of credit for \u00a0is secured by an interest in the inventory of CC Pharma GmbH as well as\u00a0the Densborn facility and underlying real property. The operating line of credit for is unsecured.
\n\u00a0
\nAmerican Beverage Crafts Group Inc. (\"ABC Group\"),\u00a0a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at SOFR plus an applicable margin. As of August 31, 2024, the Company has drawn down $10,000\u00a0on the revolving line of credit. The revolving credit facility is secured by ABC Group's assets and includes a corporate guarantee by a subsidiary of the Company.\u00a0
\n\u00a0
\n "}]},{"name":"rpt:f-707","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"us-gaap:PrimeRateMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-708","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroShorttermRateMember"},"factValues":[{"value":"0.025","decimals":3}]},{"name":"rpt:f-709","factDimensions":{"xbrl:concept":"us-gaap:DebtInstrumentBasisSpreadOnVariableRate1","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"us-gaap:LineOfCreditMember","us-gaap:VariableRateAxis":"tlry:EuroInterbankOfferedRateMember"},"factValues":[{"value":"0.04","decimals":2}]},{"name":"rpt:f-710","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:CCPharmaGmbHMember","us-gaap:ShortTermDebtTypeAxis":"tlry:OperatingLineOfCreditTwoMember"},"factValues":[{"value":"8134000","decimals":-3}]},{"name":"rpt:f-711","factDimensions":{"xbrl:concept":"us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:FourTwentyCorporationMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"30000000","decimals":-7}]},{"name":"rpt:f-712","factDimensions":{"xbrl:concept":"us-gaap:LineOfCredit","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","srt:ConsolidatedEntitiesAxis":"tlry:FourTwentyCorporationMember","us-gaap:CreditFacilityAxis":"us-gaap:RevolvingCreditFacilityMember"},"factValues":[{"value":"10000000","decimals":-7}]},{"name":"rpt:f-713","factDimensions":{"xbrl:concept":"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 11. Accounts payable and accrued liabilities
\n\u00a0
\nAccounts payable and accrued liabilities are comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Trade payables | \u00a0 | $ | 101,868 | \u00a0 | \u00a0 | $ | 105,392 | \u00a0 |
| Accrued liabilities | \u00a0 | \u00a0 | 90,899 | \u00a0 | \u00a0 | \u00a0 | 92,424 | \u00a0 |
| Litigation accrual | \u00a0 | \u00a0 | 24,413 | \u00a0 | \u00a0 | \u00a0 | 24,378 | \u00a0 |
| Accrued payroll and employment related taxes | \u00a0 | \u00a0 | 10,279 | \u00a0 | \u00a0 | \u00a0 | 6,154 | \u00a0 |
| Income taxes payable | \u00a0 | \u00a0 | 973 | \u00a0 | \u00a0 | \u00a0 | 4,092 | \u00a0 |
| Accrued interest | \u00a0 | \u00a0 | 3,359 | \u00a0 | \u00a0 | \u00a0 | 4,217 | \u00a0 |
| Sales taxes payable | \u00a0 | \u00a0 | 4,355 | \u00a0 | \u00a0 | \u00a0 | 5,300 | \u00a0 |
| Total | \u00a0 | $ | 236,146 | \u00a0 | \u00a0 | $ | 241,957 | \u00a0 |
\u00a0 \u00a0 \u00a0
\n \n \n "}]},{"name":"rpt:f-714","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Trade payables | \u00a0 | $ | 101,868 | \u00a0 | \u00a0 | $ | 105,392 | \u00a0 |
| Accrued liabilities | \u00a0 | \u00a0 | 90,899 | \u00a0 | \u00a0 | \u00a0 | 92,424 | \u00a0 |
| Litigation accrual | \u00a0 | \u00a0 | 24,413 | \u00a0 | \u00a0 | \u00a0 | 24,378 | \u00a0 |
| Accrued payroll and employment related taxes | \u00a0 | \u00a0 | 10,279 | \u00a0 | \u00a0 | \u00a0 | 6,154 | \u00a0 |
| Income taxes payable | \u00a0 | \u00a0 | 973 | \u00a0 | \u00a0 | \u00a0 | 4,092 | \u00a0 |
| Accrued interest | \u00a0 | \u00a0 | 3,359 | \u00a0 | \u00a0 | \u00a0 | 4,217 | \u00a0 |
| Sales taxes payable | \u00a0 | \u00a0 | 4,355 | \u00a0 | \u00a0 | \u00a0 | 5,300 | \u00a0 |
| Total | \u00a0 | $ | 236,146 | \u00a0 | \u00a0 | $ | 241,957 | \u00a0 |
Note 12. Long-term debt
\n\u00a0
\nThe following table sets forth the net carrying amount of long-term debt instruments:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 38,480 | \u00a0 | \u00a0 | $ | 39,420 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,154 | \u00a0 | \u00a0 | \u00a0 | 10,212 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 12,406 | \u00a0 | \u00a0 | \u00a0 | 12,422 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 245 | \u00a0 | \u00a0 | \u00a0 | 263 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,111 | \u00a0 | \u00a0 | \u00a0 | 2,089 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 320 | \u00a0 | \u00a0 | \u00a0 | 417 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 3,030 | \u00a0 | \u00a0 | \u00a0 | 3,151 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ including interest, due in | \u00a0 | \u00a0 | 19,969 | \u00a0 | \u00a0 | \u00a0 | 20,066 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 85,500 | \u00a0 | \u00a0 | \u00a0 | 86,626 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 172,215 | \u00a0 | \u00a0 | \u00a0 | 174,666 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (875 | ) | \u00a0 | \u00a0 | (808 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 171,340 | \u00a0 | \u00a0 | \u00a0 | 173,858 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (16,072 | ) | \u00a0 | \u00a0 | (15,506 | ) |
| Total noncurrent portion of long-term debt | \u00a0 | $ | 155,268 | \u00a0 | \u00a0 | $ | 158,352 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-732","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfDebtInstrumentsTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Credit facility - C$ - Canadian prime interest rate plus an applicable margin, -year term, with a -year amortization, repayable in blended monthly payments, due in | \u00a0 | $ | 38,480 | \u00a0 | \u00a0 | $ | 39,420 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 10,154 | \u00a0 | \u00a0 | \u00a0 | 10,212 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, compounded monthly, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 12,406 | \u00a0 | \u00a0 | \u00a0 | 12,422 | \u00a0 |
| Term loan - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 245 | \u00a0 | \u00a0 | \u00a0 | 263 | \u00a0 |
| Mortgage payable - C$ - Canadian prime plus %, -year term, with a -year amortization, repayable in equal monthly installments of C$ including interest, due in | \u00a0 | \u00a0 | 2,111 | \u00a0 | \u00a0 | \u00a0 | 2,089 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in quarterly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 320 | \u00a0 | \u00a0 | \u00a0 | 417 | \u00a0 |
| Term loan \u2010 \u20ac \u2010 at %, \u2010year term, repayable in monthly installments of \u20ac plus interest, due in | \u00a0 | \u00a0 | 3,030 | \u00a0 | \u00a0 | \u00a0 | 3,151 | \u00a0 |
| Mortgage payable - $ - EURIBOR rate plus %, -year term, repayable in monthly installments of $ including interest, due in | \u00a0 | \u00a0 | 19,969 | \u00a0 | \u00a0 | \u00a0 | 20,066 | \u00a0 |
| Term loan - $ - SOFR plus an applicable margin, -year term, repayable in quarterly installments of $ to $ due in | \u00a0 | \u00a0 | 85,500 | \u00a0 | \u00a0 | \u00a0 | 86,626 | \u00a0 |
| Carrying amount of long-term debt | \u00a0 | \u00a0 | 172,215 | \u00a0 | \u00a0 | \u00a0 | 174,666 | \u00a0 |
| Unamortized financing fees | \u00a0 | \u00a0 | (875 | ) | \u00a0 | \u00a0 | (808 | ) |
| Net carrying amount | \u00a0 | \u00a0 | 171,340 | \u00a0 | \u00a0 | \u00a0 | 173,858 | \u00a0 |
| Less principal portion included in current liabilities | \u00a0 | \u00a0 | (16,072 | ) | \u00a0 | \u00a0 | (15,506 | ) |
| Total noncurrent portion of long-term debt | \u00a0 | $ | 155,268 | \u00a0 | \u00a0 | $ | 158,352 | \u00a0 |
Note 13. Convertible debentures payable
\n\u00a0
\nThe following table sets forth the net carrying amount of the convertible debentures payable:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total | \u00a0 | \u00a0 | 132,650 | \u00a0 | \u00a0 | \u00a0 | 129,913 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
\u00a0
\nTLRY 27 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (39,850 | ) | \u00a0 | \u00a0 | (42,917 | ) |
| Net carrying amount | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
\u00a0
\nThe TLRY\u00a027\u00a0convertible debentures\u00a0were issued\u00a0on\u00a0 May 30, 2023 and on June 9, 2023 by way of overallotment,\u00a0in the principal amount of $172,500 (the \u201cTLRY 27 Notes\u201d). The TLRY 27 Notes\u00a0bear interest at a rate of\u00a05.20% per annum, payable semi-annually in arrears on\u00a0 June 15\u00a0and\u00a0 December 15\u00a0of each year, and mature on\u00a0 June 15, 2027,\u00a0unless earlier converted. The TLRY 27 Notes are Tilray\u2019s general unsecured obligations and rank senior in right of payment to all of Tilray\u2019s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray\u2019s unsecured indebtedness that is not so subordinated, including TLRY 23 and APHA 24, effectively junior in right of payment to any of Tilray\u2019s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray\u2019s current or future subsidiaries.\u00a0Noteholders will have the right to convert their TLRY\u00a027\u00a0Notes into shares of Tilray\u2019s common stock at their option, at any time, until the close of business on the\u00a0second\u00a0scheduled trading day immediately before\u00a0 June 15, 2027.\u00a0The initial conversion rate is\u00a0376.6478\u00a0shares per\u00a0$1,000\u00a0principal amount of TLRY\u00a027\u00a0Notes, which represents a conversion price of approximately\u00a0$2.66\u00a0per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.
\n\u00a0
\nThe TLRY\u00a027\u00a0Notes will be redeemable, in whole and\u00a0not\u00a0in part, at Tilray\u2019s option at any time on or after\u00a0\u00a0 June 20, 2025\u00a0at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray\u2019s common stock exceeds\u00a0130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders\u00a0 may\u00a0require\u00a0Tilray\u00a0to repurchase their TLRY\u00a027\u00a0Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company\u2019s offering of the TLRY\u00a027\u00a0Notes, the Company entered into a share lending agreement with an affiliate of\u00a0Jefferies LLC\u00a0(the \u201cShare Borrower\u201d), pursuant to which it lent\u00a0to the Share Borrower\u00a038,500,000\u00a0shares of the Company\u2019s common stock (the \"Borrowed Shares\"). The Borrowed Shares were newly-issued shares,\u00a0will be held as treasury shares until the expiration or early termination of the share lending agreement\u00a0and may be used by purchasers of the TLRY\u00a027\u00a0Notes\u00a0to sell up to\u00a038,500,000\u00a0shares of the Company\u2019s common stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY\u00a027\u00a0Notes. The Company did\u00a0not\u00a0receive any proceeds from the sale of the Borrowed Shares. See Note 27\u00a0(Subsequent Events), which discloses the repurchase of $7,500 of TLRY 27 Notes in an exchange transaction.\u00a0\u00a0
\n\u00a0
\nDuring the three months ended August 31, 2024, the Company recognized interest expense and\u00a0accretion of amortized discount of $2,243\u00a0and $3,067 respectively. During the three months ended August 31, 2023,\u00a0the Company recognized interest expense and\u00a0accretion of amortized discount of\u00a0$2,243 and $2,795 respectively.
\n\u00a0
\nAPHA 24 Notes
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (349,670 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 330 | \u00a0 |
\u00a0
\nThe APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bore interest at a rate of 5.25% per annum, and were payable semi-annually in arrears on June 1 and December 1 of each year, and matured on June 1, 2024\u00a0(the \"APHA 24 Notes\").\u00a0On June 1, 2024,\u00a0the Company repaid the remaining principal\u00a0of the APHA 24\u00a0Notes in cash upon maturity.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-762","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebtTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| Convertible Notes (\"TLRY 27\") | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| Convertible Notes (\"APHA 24\") | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total | \u00a0 | \u00a0 | 132,650 | \u00a0 | \u00a0 | \u00a0 | 129,913 | \u00a0 |
| Deduct - current portion | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Total convertible debentures payable, non current portion | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | 172,500 | \u00a0 | \u00a0 | $ | 172,500 | \u00a0 |
| Unamortized discount | \u00a0 | \u00a0 | (39,850 | ) | \u00a0 | \u00a0 | (42,917 | ) |
| Net carrying amount | \u00a0 | $ | 132,650 | \u00a0 | \u00a0 | $ | 129,583 | \u00a0 |
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| % Contractual debenture | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 350,000 | \u00a0 |
| Debt settlement | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (349,670 | ) |
| Fair value adjustment | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Net carrying amount | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 330 | \u00a0 |
Note 14. Warrant liability
\n\u00a0
\nAs of August 31, 2024 and May 31, 2024, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring September 17, 2025. Each warrant is exercisable for common share of the Company.
\n\u00a0
\nThe warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the nine months ended August 31, 2024, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to $1.61. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.
\n\u00a0
\nThe Company estimated the fair value of warrants outstanding as of\u00a0 August 31, 2024 at $0.412 per warrant using the Black Scholes pricing model (Level 3) with the following assumptions: Risk-free interest rate of 3.23%, expected volatility of 50%, expected term of 1.05 years, strike price of $1.61 and fair value of common stock of $1.71.
\n\u00a0
\nExpected volatility is based on both historical and implied volatility of the Company\u2019s common stock.
\n "}]},{"name":"rpt:f-799","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightOutstanding","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"6209000"}]},{"name":"rpt:f-800","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares"},"factValues":[{"value":"5.95"}]},{"name":"rpt:f-801","factDimensions":{"xbrl:concept":"us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","srt:RangeAxis":"srt:MaximumMember"},"factValues":[{"value":"1.61"}]},{"name":"rpt:f-802","factDimensions":{"xbrl:concept":"tlry:PercentageOfDailyCashPenalty","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":"0.01","decimals":2}]},{"name":"rpt:f-803","factDimensions":{"xbrl:concept":"tlry:EstimatedFairValueOfWarrantLiabilityPerWarrant","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member"},"factValues":[{"value":"0.412"}]},{"name":"rpt:f-804","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputRiskFreeInterestRateMember"},"factValues":[{"value":"3.23"}]},{"name":"rpt:f-805","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputPriceVolatilityMember"},"factValues":[{"value":"0.50","decimals":1}]},{"name":"rpt:f-806","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputExpectedTermMember"},"factValues":[{"value":"1.05"}]},{"name":"rpt:f-807","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputConversionPriceMember"},"factValues":[{"value":"1.61"}]},{"name":"rpt:f-808","factDimensions":{"xbrl:concept":"us-gaap:WarrantsAndRightsOutstandingMeasurementInput","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","us-gaap:FairValueByFairValueHierarchyLevelAxis":"us-gaap:FairValueInputsLevel3Member","us-gaap:MeasurementInputTypeAxis":"us-gaap:MeasurementInputSharePriceMember"},"factValues":[{"value":"1.71"}]},{"name":"rpt:f-809","factDimensions":{"xbrl:concept":"us-gaap:StockholdersEquityNoteDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 15. Stockholders' equity\u00a0
\n\u00a0
\nIssued and outstanding
\n\u00a0
\nAs of\u00a0\u00a0 August 31, 2024, the Company had 1,198,000,000\u00a0common shares and 10,000,000 preferred shares authorized to be issued, with\u00a0875,444,828\u00a0common shares and preferred shares issued and outstanding. Historically, the Company has issued shares of its common stock as consideration for business acquisitions, settlement of convertible notes,\u00a0settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.
\n\u00a0
\nDuring the three months ended August 31, 2024, the Company issued the following common\u00a0shares:
\n\u00a0
\n| \u00a0 | a) | 36,693,307 shares under its At-the-Market (\u201cATM\u201d) program generating\u00a0gross proceeds\u00a0of $68,279. The Company paid $1,807\u00a0in commissions and other fees associated with these issuances, with\u00a0net proceeds of $66,472. |
| \u00a0 | b) | 6,826,148 shares in connection with the exercise of previously awarded stock-based compensation awards. |
\u00a0
\nDuring the three months ended August 31, 2024\u00a0the Company granted 13,054,906 time-based RSUs,\u00a0and performance-based RSUs. During the three months ended August 31, 2023 the Company granted 11,559,549 time-based RSUs and 7,566,146 performance based RSUs.\u00a0The 7,566,146 performance based RSUs issued\u00a0contain\u00a0certain performance conditions that will not\u00a0be set until a future date\u00a0and, therefore, the grant date has not been met for accounting purposes.\u00a0The Company's total stock-based compensation expense recognized for\u00a0the\u00a0three months ended August 31, 2024\u00a0and August 31, 2023 are\u00a0as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| RSUs | \u00a0 | \u00a0 | 6,917 | \u00a0 | \u00a0 | \u00a0 | 8,257 | \u00a0 |
| Total | \u00a0 | $ | 6,917 | \u00a0 | \u00a0 | $ | 8,257 | \u00a0 |
\u00a0
\n \n \n "}]},{"name":"rpt:f-810","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesAuthorized","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"1198000000"}]},{"name":"rpt:f-811","factDimensions":{"xbrl:concept":"us-gaap:PreferredStockSharesAuthorized","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"10000000"}]},{"name":"rpt:f-812","factDimensions":{"xbrl:concept":"us-gaap:CommonStockSharesIssued","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"875444828"}]},{"name":"rpt:f-813","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesEquityFinancing","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"36693307"}]},{"name":"rpt:f-814","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodValueEquityFinancing","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"68279000","decimals":-3}]},{"name":"rpt:f-815","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"1807000","decimals":-3}]},{"name":"rpt:f-816","factDimensions":{"xbrl:concept":"tlry:NetProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"66472000","decimals":-3}]},{"name":"rpt:f-817","factDimensions":{"xbrl:concept":"us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares"},"factValues":[{"value":"6826148"}]},{"name":"rpt:f-818","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"13054906"}]},{"name":"rpt:f-819","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:TimebasedRestrictedStockUnitsMember"},"factValues":[{"value":"11559549"}]},{"name":"rpt:f-820","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-821","factDimensions":{"xbrl:concept":"us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AwardTypeAxis":"tlry:PerformancebasedRestrictedStockUnitsMember"},"factValues":[{"value":"7566146"}]},{"name":"rpt:f-822","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| RSUs | \u00a0 | \u00a0 | 6,917 | \u00a0 | \u00a0 | \u00a0 | 8,257 | \u00a0 |
| Total | \u00a0 | $ | 6,917 | \u00a0 | \u00a0 | $ | 8,257 | \u00a0 |
Note 16. Accumulated other comprehensive income (loss)
\n\u00a0
\nAccumulated other comprehensive loss includes the following components:
\n\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Foreign | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | currency | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | translation | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | gain (loss) | \u00a0 | \u00a0 | Total | \u00a0 | ||
| Balance May 31, 2023 | \u00a0 | $ | (46,610 | ) | \u00a0 | $ | (46,610 | ) |
| Other comprehensive loss | \u00a0 | \u00a0 | 3,049 | \u00a0 | \u00a0 | \u00a0 | 3,049 | \u00a0 |
| Balance August 31, 2023 | \u00a0 | $ | (43,561 | ) | \u00a0 | $ | (43,561 | ) |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Balance May 31, 2024 | \u00a0 | $ | (43,499 | ) | \u00a0 | $ | (43,499 | ) |
| Other comprehensive loss | \u00a0 | \u00a0 | 3,622 | \u00a0 | \u00a0 | \u00a0 | 3,622 | \u00a0 |
| Balance August 31, 2024 | \u00a0 | $ | (39,877 | ) | \u00a0 | $ | (39,877 | ) |
\u00a0
\n "}]},{"name":"rpt:f-828","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Foreign | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | currency | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | translation | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| \u00a0 | \u00a0 | gain (loss) | \u00a0 | \u00a0 | Total | \u00a0 | ||
| Balance May 31, 2023 | \u00a0 | $ | (46,610 | ) | \u00a0 | $ | (46,610 | ) |
| Other comprehensive loss | \u00a0 | \u00a0 | 3,049 | \u00a0 | \u00a0 | \u00a0 | 3,049 | \u00a0 |
| Balance August 31, 2023 | \u00a0 | $ | (43,561 | ) | \u00a0 | $ | (43,561 | ) |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Balance May 31, 2024 | \u00a0 | $ | (43,499 | ) | \u00a0 | $ | (43,499 | ) |
| Other comprehensive loss | \u00a0 | \u00a0 | 3,622 | \u00a0 | \u00a0 | \u00a0 | 3,622 | \u00a0 |
| Balance August 31, 2024 | \u00a0 | $ | (39,877 | ) | \u00a0 | $ | (39,877 | ) |
Note 17. Non-controlling interests
\n\u00a0
\nThe following tables summarize the information relating to the following subsidiaries of the Company\u00a0in which there is non-controlling interest;\u00a0SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.\u00a0
\n\u00a0
\nSummary of balance sheet information of the entities in which there is a non-controlling interest as of August 31, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 14 | \u00a0 | \u00a0 | $ | 108,030 | \u00a0 | \u00a0 | $ | 11 | \u00a0 | \u00a0 | $ | 108,055 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 123,694 | \u00a0 | \u00a0 | \u00a0 | 3,355 | \u00a0 | \u00a0 | \u00a0 | 159,049 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (17 | ) | \u00a0 | \u00a0 | (133,014 | ) | \u00a0 | \u00a0 | (6,993 | ) | \u00a0 | \u00a0 | (140,024 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (23,359 | ) | \u00a0 | \u00a0 | (1,451 | ) | \u00a0 | \u00a0 | (24,810 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | (3 | ) | \u00a0 | $ | 75,351 | \u00a0 | \u00a0 | $ | (5,078 | ) | \u00a0 | $ | 102,270 | \u00a0 |
\u00a0
\nSummary of balance sheet information of the entities in which there is a non-controlling interest\u00a0as of May 31, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 12 | \u00a0 | \u00a0 | $ | 95,720 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 95,735 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 124,675 | \u00a0 | \u00a0 | \u00a0 | 3,637 | \u00a0 | \u00a0 | \u00a0 | 160,312 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (9 | ) | \u00a0 | \u00a0 | (130,945 | ) | \u00a0 | \u00a0 | (6,913 | ) | \u00a0 | \u00a0 | (137,867 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (24,482 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (25,934 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 64,968 | \u00a0 | \u00a0 | $ | (4,725 | ) | \u00a0 | $ | 92,246 | \u00a0 |
\u00a0
\n \n \nSummary of income statement information of the entities in which there is a non-controlling interest\u00a0for the three months ended August 31, 2024:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 18,558 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 18,558 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5 | \u00a0 | \u00a0 | \u00a0 | 9,216 | \u00a0 | \u00a0 | \u00a0 | 630 | \u00a0 | \u00a0 | \u00a0 | 9,851 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5 | ) | \u00a0 | \u00a0 | 9,342 | \u00a0 | \u00a0 | \u00a0 | (630 | ) | \u00a0 | \u00a0 | 8,707 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | 1,041 | \u00a0 | \u00a0 | \u00a0 | 277 | \u00a0 | \u00a0 | \u00a0 | 1,317 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6 | ) | \u00a0 | $ | 10,383 | \u00a0 | \u00a0 | $ | (353 | ) | \u00a0 | $ | 10,024 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2 | ) | \u00a0 | \u00a0 | 5,088 | \u00a0 | \u00a0 | \u00a0 | (35 | ) | \u00a0 | \u00a0 | 5,051 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2 | ) | \u00a0 | $ | 5,088 | \u00a0 | \u00a0 | $ | (35 | ) | \u00a0 | $ | 5,051 | \u00a0 |
\u00a0
\nSummary of income statement information of the entities in which there is a non-controlling interest\u00a0for the three months ended August 31,\u00a02023:
\n\u00a0
\n \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,230 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,230 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 35 | \u00a0 | \u00a0 | \u00a0 | 15,636 | \u00a0 | \u00a0 | \u00a0 | 216 | \u00a0 | \u00a0 | \u00a0 | 15,887 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (35 | ) | \u00a0 | \u00a0 | 23,594 | \u00a0 | \u00a0 | \u00a0 | (216 | ) | \u00a0 | \u00a0 | 23,343 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (20 | ) | \u00a0 | \u00a0 | 533 | \u00a0 | \u00a0 | \u00a0 | (345 | ) | \u00a0 | \u00a0 | 168 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (55 | ) | \u00a0 | $ | 24,127 | \u00a0 | \u00a0 | $ | (561 | ) | \u00a0 | $ | 23,511 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (14 | ) | \u00a0 | \u00a0 | 11,822 | \u00a0 | \u00a0 | \u00a0 | (56 | ) | \u00a0 | \u00a0 | 11,752 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,070 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,070 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (14 | ) | \u00a0 | $ | 15,892 | \u00a0 | \u00a0 | $ | (56 | ) | \u00a0 | $ | 15,822 | \u00a0 |
\u00a0 \u00a0 \u00a0\u00a0
\n "}]},{"name":"rpt:f-842","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:SuperheroAcquisitionLPMember"},"factValues":[{"value":"0.68","decimals":2}]},{"name":"rpt:f-843","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:CCPharmaNordicApSMember"},"factValues":[{"value":"0.75","decimals":2}]},{"name":"rpt:f-844","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:AphriaDiamondMember"},"factValues":[{"value":"0.51","decimals":2}]},{"name":"rpt:f-845","factDimensions":{"xbrl:concept":"us-gaap:MinorityInterestOwnershipPercentageByParent","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","srt:OwnershipAxis":"tlry:ColCannaSASMember"},"factValues":[{"value":"0.90","decimals":1}]},{"name":"rpt:f-846","factDimensions":{"xbrl:concept":"srt:ScheduleOfCondensedBalanceSheetTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 14 | \u00a0 | \u00a0 | $ | 108,030 | \u00a0 | \u00a0 | $ | 11 | \u00a0 | \u00a0 | $ | 108,055 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 123,694 | \u00a0 | \u00a0 | \u00a0 | 3,355 | \u00a0 | \u00a0 | \u00a0 | 159,049 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (17 | ) | \u00a0 | \u00a0 | (133,014 | ) | \u00a0 | \u00a0 | (6,993 | ) | \u00a0 | \u00a0 | (140,024 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (23,359 | ) | \u00a0 | \u00a0 | (1,451 | ) | \u00a0 | \u00a0 | (24,810 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | (3 | ) | \u00a0 | $ | 75,351 | \u00a0 | \u00a0 | $ | (5,078 | ) | \u00a0 | $ | 102,270 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | May 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Current assets | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 12 | \u00a0 | \u00a0 | $ | 95,720 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 95,735 | \u00a0 |
| Non-current assets | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 124,675 | \u00a0 | \u00a0 | \u00a0 | 3,637 | \u00a0 | \u00a0 | \u00a0 | 160,312 | \u00a0 |
| Current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (9 | ) | \u00a0 | \u00a0 | (130,945 | ) | \u00a0 | \u00a0 | (6,913 | ) | \u00a0 | \u00a0 | (137,867 | ) |
| Non-current liabilities | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (24,482 | ) | \u00a0 | \u00a0 | (1,452 | ) | \u00a0 | \u00a0 | (25,934 | ) |
| Net assets | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 3 | \u00a0 | \u00a0 | $ | 64,968 | \u00a0 | \u00a0 | $ | (4,725 | ) | \u00a0 | $ | 92,246 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2024 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 18,558 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 18,558 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 5 | \u00a0 | \u00a0 | \u00a0 | 9,216 | \u00a0 | \u00a0 | \u00a0 | 630 | \u00a0 | \u00a0 | \u00a0 | 9,851 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (5 | ) | \u00a0 | \u00a0 | 9,342 | \u00a0 | \u00a0 | \u00a0 | (630 | ) | \u00a0 | \u00a0 | 8,707 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (1 | ) | \u00a0 | \u00a0 | 1,041 | \u00a0 | \u00a0 | \u00a0 | 277 | \u00a0 | \u00a0 | \u00a0 | 1,317 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (6 | ) | \u00a0 | $ | 10,383 | \u00a0 | \u00a0 | $ | (353 | ) | \u00a0 | $ | 10,024 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2 | ) | \u00a0 | \u00a0 | 5,088 | \u00a0 | \u00a0 | \u00a0 | (35 | ) | \u00a0 | \u00a0 | 5,051 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2 | ) | \u00a0 | $ | 5,088 | \u00a0 | \u00a0 | $ | (35 | ) | \u00a0 | $ | 5,051 | \u00a0 |
| \u00a0 | \u00a0 | SH | \u00a0 | \u00a0 | CC Pharma | \u00a0 | \u00a0 | Aphria | \u00a0 | \u00a0 | ColCanna | \u00a0 | \u00a0 | August 31, | \u00a0 | |||||
| \u00a0 | \u00a0 | Acquisition | \u00a0 | \u00a0 | Nordic ApS | \u00a0 | \u00a0 | Diamond | \u00a0 | \u00a0 | S.A.S. | \u00a0 | \u00a0 | 2023 | \u00a0 | |||||
| Revenue | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,230 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 39,230 | \u00a0 |
| Total expenses | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 35 | \u00a0 | \u00a0 | \u00a0 | 15,636 | \u00a0 | \u00a0 | \u00a0 | 216 | \u00a0 | \u00a0 | \u00a0 | 15,887 | \u00a0 |
| Net (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (35 | ) | \u00a0 | \u00a0 | 23,594 | \u00a0 | \u00a0 | \u00a0 | (216 | ) | \u00a0 | \u00a0 | 23,343 | \u00a0 |
| Other comprehensive (loss) income | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (20 | ) | \u00a0 | \u00a0 | 533 | \u00a0 | \u00a0 | \u00a0 | (345 | ) | \u00a0 | \u00a0 | 168 | \u00a0 |
| Net comprehensive (loss) income | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (55 | ) | \u00a0 | $ | 24,127 | \u00a0 | \u00a0 | $ | (561 | ) | \u00a0 | $ | 23,511 | \u00a0 |
| Non-controlling interest % | \u00a0 | \u00a0 | 32 | % | \u00a0 | \u00a0 | 25 | % | \u00a0 | \u00a0 | 49 | % | \u00a0 | \u00a0 | 10 | % | \u00a0 | NA | \u00a0 | |
| Comprehensive (loss) income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (14 | ) | \u00a0 | \u00a0 | 11,822 | \u00a0 | \u00a0 | \u00a0 | (56 | ) | \u00a0 | \u00a0 | 11,752 | \u00a0 |
| Additional income attributable to NCI | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,070 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 4,070 | \u00a0 |
| Net comprehensive (loss) income attributable to NCI | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (14 | ) | \u00a0 | $ | 15,892 | \u00a0 | \u00a0 | $ | (56 | ) | \u00a0 | $ | 15,822 | \u00a0 |
Note 18. Income taxes
\n\u00a0
\nThe determination of the Company\u2019s overall effective\u00a0tax\u00a0rate requires significant judgment, the use of estimates, and the interpretation and application of complex\u00a0tax\u00a0laws. The effective\u00a0tax\u00a0rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions.\u00a0Tax\u00a0law changes, increases, and decreases in temporary and permanent differences between book and\u00a0tax\u00a0items, valuation allowances against the deferred tax assets, stock compensation, and the Company\u2019s change in income in each jurisdiction all affect the overall effective\u00a0tax\u00a0rate. It is the Company\u2019s practice to recognize interest and penalties related to uncertain\u00a0tax\u00a0positions in income\u00a0tax\u00a0expense.
\n\u00a0
\nThe Company reported income tax expense of $886\u00a0for the three months ended August 31, 2024, and\u00a0income tax expense of $7,264\u00a0for the three months ended August 31,\u00a02023. The income tax benefit\u00a0in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-982","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"886000","decimals":-3}]},{"name":"rpt:f-983","factDimensions":{"xbrl:concept":"us-gaap:IncomeTaxExpenseBenefit","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"7264000","decimals":-3}]},{"name":"rpt:f-984","factDimensions":{"xbrl:concept":"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 19. Commitments and contingencies
\n\u00a0
\nPurchase and other commitments
\n\u00a0
\nThe Company has payments on long-term debt, refer to Note 12\u00a0(Long-term debt), convertible notes, refer to Note 13\u00a0(Convertible debentures payable), material purchase commitments and construction commitments as follows:
\n\u00a0
\n \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 172,215 | \u00a0 | \u00a0 | $ | 16,072 | \u00a0 | \u00a0 | $ | 42,563 | \u00a0 | \u00a0 | $ | 12,604 | \u00a0 | \u00a0 | $ | 66,762 | \u00a0 | \u00a0 | $ | 34,214 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 67,142 | \u00a0 | \u00a0 | \u00a0 | 39,615 | \u00a0 | \u00a0 | \u00a0 | 27,527 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| Construction commitments | \u00a0 | \u00a0 | 431 | \u00a0 | \u00a0 | \u00a0 | 431 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 412,288 | \u00a0 | \u00a0 | $ | 56,118 | \u00a0 | \u00a0 | $ | 70,090 | \u00a0 | \u00a0 | $ | 185,104 | \u00a0 | \u00a0 | $ | 66,762 | \u00a0 | \u00a0 | $ | 34,214 | \u00a0 |
\u00a0
\nLegal proceedings
\n\u00a0
\nIn the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves\u00a0 may\u00a0be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is\u00a0not\u00a0probable or the amount of loss is\u00a0not\u00a0estimable, we do\u00a0not\u00a0accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are\u00a0not\u00a0expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable,\u00a0 may\u00a0be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.
\n\u00a0
\nThere have been no material changes from the legal proceedings since\u00a0our Annual Report on Form 10-K\u00a0for the fiscal year ended May 31, 2024, except with respect to the legal proceeding disclosed below that was dismissed with prejudice on September 30, 2024:
\n\u00a0
\nAuthentic Brands Group Related Class Action (New York, United States)
\n\u00a0
\nOn May 4, 2020, Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York (\u201cSDNY\u201d), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the \u201cKasilingam litigation\u201d). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company\u2019s revenue sharing agreement with Authentic Brands Group (\u201cABG\u201d), announced on January 15, 2019, and that the plaintiff suffered losses when Tilray\u2019s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020.
\n\u00a0
\nOn September 27, 2021, the U.S. District Court entered an Opinion & Order granting the Defendants\u2019 motion to dismiss the complaint in the Kasilingam litigation without prejudice. On December 3, 2021, the lead plaintiff filed a second amended complaint alleging similar claims against Tilray and Brendan Kennedy. The Defendants successfully moved to dismiss the second amended complaint on February 2, 2022. In dismissing the second amended complaint, the court granted the Plaintiff leave to amend one final time. On September 27, 2023, the Plaintiff filed its Third Amended Complaint.
\n\u00a0
\nOn September 30, 2024, the U.S. District Court entered an Opinion & Order granting the Defendants\u2019 motion to dismiss the Third Amended Complaint in the Kasilingam litigation with prejudice.
\n\u00a0
\nIn the Matter of an Arbitration Between: K. Dickson v. Tilray, Inc.
\n\u00a0
\nIn 2021, Ms. Dickson, the former President of Manitoba Harvest, a wholly-owned subsidiary of Tilray, commenced an arbitration in Minneapolis, Minnesota against Tilray, alleging that Tilray materially breached her Employment Agreement with Tilray and asserted certain Washington statutory wage claims.
\n\u00a0
\nOn March 17, 2023, the arbitrator awarded Dickson $3,734 in damages, plus amounts for pre-judgment, and double damages under a Washington state wage payment statute (the \u201cArbitration Award\u201d). Tilray\u2019s counterclaim was denied by the Arbitrator. On May 23, 2023, the arbitrator issued a supplemental award which provided that Dickson was entitled to recover attorney fees and costs from Tilray in connection with the arbitration.\u00a0 On February 27, 2024, the U.S. District Court for the Western District of Washington dismissed as moot Tilray\u2019s petition to vacate, modify or correct the Arbitration Award, granting Dickson\u2019s responding motion to dismiss on the basis that the U.S. District Court for the Western District of Washington lacked personal jurisdiction over Dickson. On March 15, 2024, Tilray filed its notice of appeal of the decision of the U.S. District Court for the Western District of Washington to the U.S. Court of Appeals for the Ninth Circuit. On August 8, 2024, the District Court in Minnesota confirmed the Arbitration Award. A judgment on the Award was entered by the Court on August 12, 2024, and, following a motion to correct the judgment, became final on September 27, 2024.\u00a0Tilray\u00a0filed a notice of appeal to the U.S. Court of Appeals for the Eighth Circuit, which\u00a0appeal is still pending. The parties are finalizing a settlement of this matter, pursuant to which Tilray intends to pay the amount of the Arbitration Award in satisfaction of the related judgment.\u00a0
\n\u00a0
\nSummary of litigation accruals\u00a0
\n\u00a0
\nAs described in Note 11\u00a0(Accounts payable and accrued liabilities), the total litigation\u00a0expense accrual included in accrued liabilities as of\u00a0 August 31, 2024 was equal to\u00a0$24,413. This accrual is intended to cover various ongoing litigation matters that are currently probable and estimable. For the period ended May 31, 2024,\u00a0the total litigation\u00a0expense accrual included in accrued liabilities was $24,378.
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-985","factDimensions":{"xbrl:concept":"srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | Total | \u00a0 | \u00a0 | 2025 | \u00a0 | \u00a0 | 2026 | \u00a0 | \u00a0 | 2027 | \u00a0 | \u00a0 | 2028 | \u00a0 | \u00a0 | Thereafter | \u00a0 | ||||||
| Long-term debt repayment | \u00a0 | $ | 172,215 | \u00a0 | \u00a0 | $ | 16,072 | \u00a0 | \u00a0 | $ | 42,563 | \u00a0 | \u00a0 | $ | 12,604 | \u00a0 | \u00a0 | $ | 66,762 | \u00a0 | \u00a0 | $ | 34,214 | \u00a0 |
| Convertible debentures payable | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 172,500 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Material purchase obligations | \u00a0 | \u00a0 | 67,142 | \u00a0 | \u00a0 | \u00a0 | 39,615 | \u00a0 | \u00a0 | \u00a0 | 27,527 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | |
| Construction commitments | \u00a0 | \u00a0 | 431 | \u00a0 | \u00a0 | \u00a0 | 431 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total | \u00a0 | $ | 412,288 | \u00a0 | \u00a0 | $ | 56,118 | \u00a0 | \u00a0 | $ | 70,090 | \u00a0 | \u00a0 | $ | 185,104 | \u00a0 | \u00a0 | $ | 66,762 | \u00a0 | \u00a0 | $ | 34,214 | \u00a0 |
Note 20. Net revenue
\n\u00a0
\nThe Company reports net revenue in\u00a0four\u00a0reporting segments: beverage alcohol, cannabis, distribution, and wellness.\u00a0
\n\u00a0
\nNet revenue is comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol revenue | \u00a0 | $ | 59,163 | \u00a0 | \u00a0 | $ | 25,339 | \u00a0 |
| Beverage alcohol excise taxes | \u00a0 | \u00a0 | (3,191 | ) | \u00a0 | \u00a0 | (1,177 | ) |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 55,972 | \u00a0 | \u00a0 | \u00a0 | 24,162 | \u00a0 |
| Cannabis revenue | \u00a0 | \u00a0 | 81,194 | \u00a0 | \u00a0 | \u00a0 | 96,884 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (19,945 | ) | \u00a0 | \u00a0 | (26,551 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 61,249 | \u00a0 | \u00a0 | \u00a0 | 70,333 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 68,071 | \u00a0 | \u00a0 | \u00a0 | 69,157 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,752 | \u00a0 | \u00a0 | \u00a0 | 13,297 | \u00a0 |
| Total | \u00a0 | $ | 200,044 | \u00a0 | \u00a0 | $ | 176,949 | \u00a0 |
\u00a0\u00a0
\n "}]},{"name":"rpt:f-1020","factDimensions":{"xbrl:concept":"us-gaap:DisaggregationOfRevenueTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol revenue | \u00a0 | $ | 59,163 | \u00a0 | \u00a0 | $ | 25,339 | \u00a0 |
| Beverage alcohol excise taxes | \u00a0 | \u00a0 | (3,191 | ) | \u00a0 | \u00a0 | (1,177 | ) |
| Net beverage alcohol revenue | \u00a0 | \u00a0 | 55,972 | \u00a0 | \u00a0 | \u00a0 | 24,162 | \u00a0 |
| Cannabis revenue | \u00a0 | \u00a0 | 81,194 | \u00a0 | \u00a0 | \u00a0 | 96,884 | \u00a0 |
| Cannabis excise taxes | \u00a0 | \u00a0 | (19,945 | ) | \u00a0 | \u00a0 | (26,551 | ) |
| Net cannabis revenue | \u00a0 | \u00a0 | 61,249 | \u00a0 | \u00a0 | \u00a0 | 70,333 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 68,071 | \u00a0 | \u00a0 | \u00a0 | 69,157 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,752 | \u00a0 | \u00a0 | \u00a0 | 13,297 | \u00a0 |
| Total | \u00a0 | $ | 200,044 | \u00a0 | \u00a0 | $ | 176,949 | \u00a0 |
Note 21. Cost of goods sold
\n\u00a0
\nCost of goods sold is comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol costs | \u00a0 | $ | 33,050 | \u00a0 | \u00a0 | $ | 11,266 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 37,054 | \u00a0 | \u00a0 | \u00a0 | 50,517 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,138 | \u00a0 | \u00a0 | \u00a0 | 61,468 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,096 | \u00a0 | \u00a0 | \u00a0 | 9,502 | \u00a0 |
| Total | \u00a0 | $ | 140,338 | \u00a0 | \u00a0 | $ | 132,753 | \u00a0 |
\u00a0 \u00a0 \u00a0
\n "}]},{"name":"rpt:f-1040","factDimensions":{"xbrl:concept":"tlry:ScheduleOfCostOfGoodsSoldTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol costs | \u00a0 | $ | 33,050 | \u00a0 | \u00a0 | $ | 11,266 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 37,054 | \u00a0 | \u00a0 | \u00a0 | 50,517 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,138 | \u00a0 | \u00a0 | \u00a0 | 61,468 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,096 | \u00a0 | \u00a0 | \u00a0 | 9,502 | \u00a0 |
| Total | \u00a0 | $ | 140,338 | \u00a0 | \u00a0 | $ | 132,753 | \u00a0 |
Note 22. General and administrative expenses
\n\u00a0
\nGeneral and administrative expenses are comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Salaries and wages | \u00a0 | $ | 21,567 | \u00a0 | \u00a0 | $ | 16,775 | \u00a0 |
| Office and general | \u00a0 | \u00a0 | 9,260 | \u00a0 | \u00a0 | \u00a0 | 8,168 | \u00a0 |
| Stock-based compensation | \u00a0 | \u00a0 | 6,917 | \u00a0 | \u00a0 | \u00a0 | 8,257 | \u00a0 |
| Insurance | \u00a0 | \u00a0 | 2,455 | \u00a0 | \u00a0 | \u00a0 | 3,849 | \u00a0 |
| Professional fees | \u00a0 | \u00a0 | 1,178 | \u00a0 | \u00a0 | \u00a0 | 1,499 | \u00a0 |
| (Gain) loss on sale of capital assets | \u00a0 | \u00a0 | (26 | ) | \u00a0 | \u00a0 | 3 | \u00a0 |
| Travel and accommodation | \u00a0 | \u00a0 | 1,493 | \u00a0 | \u00a0 | \u00a0 | 1,107 | \u00a0 |
| Rent | \u00a0 | \u00a0 | 1,269 | \u00a0 | \u00a0 | \u00a0 | 858 | \u00a0 |
| Total | \u00a0 | $ | 44,113 | \u00a0 | \u00a0 | $ | 40,516 | \u00a0 |
\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1052","factDimensions":{"xbrl:concept":"tlry:ScheduleOfGeneralAndAdministrativeExpensesTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Salaries and wages | \u00a0 | $ | 21,567 | \u00a0 | \u00a0 | $ | 16,775 | \u00a0 |
| Office and general | \u00a0 | \u00a0 | 9,260 | \u00a0 | \u00a0 | \u00a0 | 8,168 | \u00a0 |
| Stock-based compensation | \u00a0 | \u00a0 | 6,917 | \u00a0 | \u00a0 | \u00a0 | 8,257 | \u00a0 |
| Insurance | \u00a0 | \u00a0 | 2,455 | \u00a0 | \u00a0 | \u00a0 | 3,849 | \u00a0 |
| Professional fees | \u00a0 | \u00a0 | 1,178 | \u00a0 | \u00a0 | \u00a0 | 1,499 | \u00a0 |
| (Gain) loss on sale of capital assets | \u00a0 | \u00a0 | (26 | ) | \u00a0 | \u00a0 | 3 | \u00a0 |
| Travel and accommodation | \u00a0 | \u00a0 | 1,493 | \u00a0 | \u00a0 | \u00a0 | 1,107 | \u00a0 |
| Rent | \u00a0 | \u00a0 | 1,269 | \u00a0 | \u00a0 | \u00a0 | 858 | \u00a0 |
| Total | \u00a0 | $ | 44,113 | \u00a0 | \u00a0 | $ | 40,516 | \u00a0 |
Note 23. Restructuring charges
\n\u00a0
\nIn connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these non-recurring transactions. The Company recognized $4,247\u00a0of restructuring charges for the three months ended August 31, 2024\u00a0compared to $915\u00a0for the prior year period. All restructuring\u00a0plans are approved at the executive level and their associated expenses are recognized in\u00a0the period in which the plan has been committed to. All amounts incurred as of\u00a0 August 31, 2024, have been paid.\u00a0
\n\u00a0
\nWithin the Cannabis segment, our restructuring costs predominantly related to\u00a0the\u00a0HEXO acquisition, which are expected to be completed within 24 months from the original acquisition date in June 2023. In the three months ended August 31, 2024, we\u00a0recognized\u00a0$2,582\u00a0of employee termination benefits and costs related to\u00a0the conversion from cannabis to produce at HEXO's Quebec cultivation facility (which is currently held for sale),\u00a0the optimization of our Redecan facilities, and\u00a0$255 of restructuring charges related to the remaining costs of exiting the Truss facility following its sale to a third party in the previous fiscal year ended May 31, 2024. Additionally, the Company recognized $82 of cost associated winding down the Fort Collins warehouse currently held for sale.\u00a0
\n\u00a0
\nWithin the Distribution segment, the Company recognized $121 of restructuring charges for its Argentinean pharmacy business.\u00a0
\n\u00a0
\nWithin the beverage\u00a0alcohol segment, the Company recognized\u00a0$123\u00a0of employee termination benefits through the integration of the Craft acquisition.\u00a0
\n\u00a0
\nLastly, for the\u00a0three months ended August 31, 2024, the Company recognized $1,084 of cost associated with the investment held in Superhero (SH)\u00a0as a result of MedMen\u2019s ongoing restructuring and/or liquidation undertakings.
\n\u00a0
\n "}]},{"name":"rpt:f-1072","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"4247000","decimals":-3}]},{"name":"rpt:f-1073","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2023-06-01T00:00:00/2023-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD"},"factValues":[{"value":"915000","decimals":-3}]},{"name":"rpt:f-1074","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:HexoAcquisitionMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember"},"factValues":[{"value":"2582000","decimals":-3}]},{"name":"rpt:f-1075","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:TrussBeverageCompanyMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember"},"factValues":[{"value":"255000","decimals":-3}]},{"name":"rpt:f-1076","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:PropertyPlantAndEquipmentByTypeAxis":"tlry:FortCollinsFacilityMember","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:FacilityClosingMember"},"factValues":[{"value":"82000","decimals":-3}]},{"name":"rpt:f-1077","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:StatementBusinessSegmentsAxis":"tlry:DistributionBusinessMember"},"factValues":[{"value":"121000","decimals":-3}]},{"name":"rpt:f-1078","factDimensions":{"xbrl:concept":"us-gaap:RestructuringCosts","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:RestructuringCostAndReserveAxis":"us-gaap:EmployeeSeveranceMember","us-gaap:StatementBusinessSegmentsAxis":"tlry:BeverageAlcoholBusinessMember"},"factValues":[{"value":"123000","decimals":-3}]},{"name":"rpt:f-1079","factDimensions":{"xbrl:concept":"us-gaap:RestructuringAndRelatedCostIncurredCost","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:SuperheroLPMember"},"factValues":[{"value":"1084000","decimals":-3}]},{"name":"rpt:f-1080","factDimensions":{"xbrl:concept":"us-gaap:OtherNonoperatingIncomeAndExpenseTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \nNote 24. Non-operating income (expense), net
\n\u00a0
\nNon-operating income (expense), net is comprised of:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Change in fair value of convertible debenture payable | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2,147 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 696 | \u00a0 | \u00a0 | \u00a0 | (8,198 | ) |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | 11,881 | \u00a0 | \u00a0 | \u00a0 | 6,267 | \u00a0 |
| Loss on long-term investments | \u00a0 | \u00a0 | (39 | ) | \u00a0 | \u00a0 | (109 | ) |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | 108 | \u00a0 | \u00a0 | \u00a0 | (215 | ) |
| Total | \u00a0 | $ | 12,646 | \u00a0 | \u00a0 | $ | (4,402 | ) |
\u00a0
\n "}]},{"name":"rpt:f-1081","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Change in fair value of convertible debenture payable | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | (2,147 | ) |
| Change in fair value of warrant liability | \u00a0 | \u00a0 | 696 | \u00a0 | \u00a0 | \u00a0 | (8,198 | ) |
| Foreign exchange gain (loss) | \u00a0 | \u00a0 | 11,881 | \u00a0 | \u00a0 | \u00a0 | 6,267 | \u00a0 |
| Loss on long-term investments | \u00a0 | \u00a0 | (39 | ) | \u00a0 | \u00a0 | (109 | ) |
| Other non-operating (losses) gains, net | \u00a0 | \u00a0 | 108 | \u00a0 | \u00a0 | \u00a0 | (215 | ) |
| Total | \u00a0 | $ | 12,646 | \u00a0 | \u00a0 | $ | (4,402 | ) |
Note 25. Fair value measurements
\n\u00a0
\nFinancial instruments
\n\u00a0
\nThe Company has classified its financial instruments as described in Note 3 (Significant accounting policies) in our Annual Financial Statements.
\n\u00a0
\nThe carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.
\n\u00a0
\nOn\u00a0 August 31, 2024\u00a0and\u00a0 May 31, 2024\u00a0the Company had long-term debt of $3,350\u00a0and $3,568, respectively,\u00a0and the principal portion of convertible debentures payable of $172,500\u00a0and $172,830, respectively,\u00a0subject to fixed interest rates. The Company\u2019s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.
\n\u00a0
\n \n \nThe following tables present information about the Company\u2019s assets and liabilities that are measured at fair value on a recurring basis as of August 31, 2024 and\u00a0 May 31, 2024 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | August 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 205,186 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 205,186 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 74,869 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 74,869 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 891 | \u00a0 | \u00a0 | \u00a0 | 1,462 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,853 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2,557 | ) | \u00a0 | \u00a0 | (2,557 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 280,946 | \u00a0 | \u00a0 | $ | 1,462 | \u00a0 | \u00a0 | $ | 19,943 | \u00a0 | \u00a0 | $ | 302,351 | \u00a0 |
\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 228,340 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 228,340 | \u00a0 |
| Marketable Securities | \u00a0 | \u00a0 | 32,182 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,182 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 919 | \u00a0 | \u00a0 | \u00a0 | 1,440 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,859 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,253 | ) | \u00a0 | \u00a0 | (3,253 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (330 | ) | \u00a0 | \u00a0 | (330 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,441 | \u00a0 | \u00a0 | $ | 1,440 | \u00a0 | \u00a0 | $ | 18,917 | \u00a0 | \u00a0 | $ | 281,798 | \u00a0 |
\u00a0
\nThe Company\u2019s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability.
\n\u00a0
\nConvertible notes receivable and long-term investments are recorded at fair value. The estimated fair value is determined using, among\u00a0others,\u00a0the Black Scholes option pricing model, probability of legalization and is classified as Level\u00a03.
\n\u00a0
\nConvertible debentures payable are recorded at fair value when elected or required under US GAAP. Specifically, the APHA\u00a024\u00a0instrument's estimated fair value was\u00a0determined using the Black-Scholes option pricing model and was\u00a0classified as Level\u00a03.\u00a0
\n\u00a0
\nCertain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level\u00a01. The\u00a0Company classified securities with observable inputs as Level\u00a02\u00a0and without a quoted market price as Level\u00a03.
\n\u00a0
\nThe warrants associated with the warrant liability are classified as Level\u00a03\u00a0derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders\u2019 equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.
\n\u00a0
\nA portion of the consideration to be paid in connection the Company\u2019s acquisition\u00a0of Montauk Brewing is contingent upon the achievement of certain financial measures as of December 2025, and if achieved, such contingent consideration is payable in cash. The contingent consideration amount\u00a0was estimated by applying a\u00a0probability of achievement of 100% on the $15,000 sales earn-out component and 0% on the remaining criterion, which is not expected to be achieved. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level\u00a03.
\n\u00a0
\nDuring the three months ended August 31, 2024, a decrease in fair value of \u00a0was recognized compared to a decrease of fair value of $11,107 in the period ended August 31, 2023 for the contingent consideration from the SweetWater acquisition as a result of not\u00a0achieving the incentive targets.\u00a0
\n\u00a0
\nThe balances of assets and liabilities categorized within Level\u00a03\u00a0of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:
\n\u00a0
\n \n \n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(Repayments) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Redemption | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 696 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, August 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (2,557 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
\u00a0
\nThe unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:
\n\u00a0
\n \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 1.0 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Probability of achievement | \u00a0 |
| \u00a0 |
\u00a0
\nItems measured at fair value on a non-recurring basis
\n\u00a0
\nThe Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.
\n\u00a0
\nManagement reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company\u2019s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.
\n "}]},{"name":"rpt:f-1095","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"3350000","decimals":-4}]},{"name":"rpt:f-1096","factDimensions":{"xbrl:concept":"us-gaap:LongtermDebtPercentageBearingFixedInterestAmount","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"tlry:LongtermDebtExcludingConvertibleDebenturesMember"},"factValues":[{"value":"3568000","decimals":-3}]},{"name":"rpt:f-1097","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-09-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"172500000","decimals":-5}]},{"name":"rpt:f-1098","factDimensions":{"xbrl:concept":"us-gaap:ConvertibleDebt","xbrl:period":"2024-06-01T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:LongtermDebtTypeAxis":"us-gaap:ConvertibleDebtMember"},"factValues":[{"value":"172830000","decimals":-4}]},{"name":"rpt:f-1099","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | August 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 205,186 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 205,186 | \u00a0 |
| Marketable securities | \u00a0 | \u00a0 | 74,869 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 74,869 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 891 | \u00a0 | \u00a0 | \u00a0 | 1,462 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,853 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (2,557 | ) | \u00a0 | \u00a0 | (2,557 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Total recurring fair value measurements | \u00a0 | $ | 280,946 | \u00a0 | \u00a0 | $ | 1,462 | \u00a0 | \u00a0 | $ | 19,943 | \u00a0 | \u00a0 | $ | 302,351 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | May 31, | \u00a0 | |
| \u00a0 | \u00a0 | Level 1 | \u00a0 | \u00a0 | Level 2 | \u00a0 | \u00a0 | Level 3 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||||
| Financial assets | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Cash and cash equivalents | \u00a0 | $ | 228,340 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | \u2014 | \u00a0 | \u00a0 | $ | 228,340 | \u00a0 |
| Marketable Securities | \u00a0 | \u00a0 | 32,182 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,182 | \u00a0 |
| Convertible notes receivable | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 | \u00a0 | \u00a0 | 32,000 | \u00a0 |
| Equity investments measured at fair value | \u00a0 | \u00a0 | 919 | \u00a0 | \u00a0 | \u00a0 | 1,440 | \u00a0 | \u00a0 | \u00a0 | 5,500 | \u00a0 | \u00a0 | \u00a0 | 7,859 | \u00a0 |
| Financial liabilities | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Warrant liability | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (3,253 | ) | \u00a0 | \u00a0 | (3,253 | ) |
| Contingent consideration | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (15,000 | ) | \u00a0 | \u00a0 | (15,000 | ) |
| APHA 24 Convertible debenture | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | (330 | ) | \u00a0 | \u00a0 | (330 | ) |
| Total recurring fair value measurements | \u00a0 | $ | 261,441 | \u00a0 | \u00a0 | $ | 1,440 | \u00a0 | \u00a0 | $ | 18,917 | \u00a0 | \u00a0 | $ | 281,798 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | APHA 24 | \u00a0 | |
| \u00a0 | \u00a0 | Convertible | \u00a0 | \u00a0 | Equity | \u00a0 | \u00a0 | Warrant | \u00a0 | \u00a0 | Contingent | \u00a0 | \u00a0 | Convertible | \u00a0 | |||||
| \u00a0 | \u00a0 | notes receivable | \u00a0 | \u00a0 | Investments | \u00a0 | \u00a0 | Liability | \u00a0 | \u00a0 | Consideration | \u00a0 | \u00a0 | Debt | \u00a0 | |||||
| Balance, May 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (3,253 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | (330 | ) |
| Additions/(Repayments) | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 330 | \u00a0 |
| Redemption | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Unrealized gain (loss) on fair value | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | 696 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Impairments | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 | \u00a0 | \u00a0 | \u2014 | \u00a0 |
| Balance, August 31, 2024 | \u00a0 | $ | 32,000 | \u00a0 | \u00a0 | $ | 5,500 | \u00a0 | \u00a0 | $ | (2,557 | ) | \u00a0 | $ | (15,000 | ) | \u00a0 | $ | \u2014 | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Significant | \u00a0 | \u00a0 | \u00a0 |
| \u00a0 | \u00a0 | Valuation | \u00a0 | unobservable | \u00a0 | \u00a0 | |
| Financial asset / financial liability | \u00a0 | technique | \u00a0 | input | \u00a0 | Inputs | \u00a0 |
| Warrant liability | \u00a0 | Black-Scholes | \u00a0 | Volatility, | \u00a0 | 50% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | expected life (in years) | \u00a0 | 1.0 | \u00a0 |
| Contingent consideration | \u00a0 | Discounted cash flows | \u00a0 | Discount rate, | \u00a0 | 11% | \u00a0 |
| \u00a0 | \u00a0 | \u00a0 | \u00a0 | Probability of achievement | \u00a0 |
| \u00a0 |
Note 26. Segment reporting
\n\u00a0
\nInformation reported to the Chief Operating Decision Maker (\u201cCODM\u201d) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in\u00a0 reportable segments:\u00a0(1) beverage alcohol operations, which encompasses the production, marketing and sale of beverage and beverage alcohol products, (2) cannabis operations, which encompasses the cultivation, production, distribution,\u00a0sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (3) distribution operations, which encompasses the purchase and resale/distribution of pharmaceuticals products to wholesale and pharmacy customers, and (4) wellness products, which encompasses hemp foods and hemp-based cannabidiol (\u201cCBD\u201d) consumer products. This structure is in line with how our Chief Operating Decision Maker (\u201cCODM\u201d) assesses our performance and allocates resources.\u00a0
\n\u00a0
\nOperating segments have not been aggregated and no asset information is provided for the segments because the Company\u2019s CODM does not receive asset information by segment on a regular basis.\u00a0
\n\u00a0
\n \n \nSegment gross profit from external customers:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage alcohol revenue | \u00a0 | $ | 55,972 | \u00a0 | \u00a0 | $ | 24,162 | \u00a0 |
| Beverage alcohol costs | \u00a0 | \u00a0 | 33,050 | \u00a0 | \u00a0 | \u00a0 | 11,266 | \u00a0 |
| Beverage alcohol gross profit | \u00a0 | \u00a0 | 22,922 | \u00a0 | \u00a0 | \u00a0 | 12,896 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 61,249 | \u00a0 | \u00a0 | \u00a0 | 70,333 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 37,054 | \u00a0 | \u00a0 | \u00a0 | 50,517 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 24,195 | \u00a0 | \u00a0 | \u00a0 | 19,816 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 68,071 | \u00a0 | \u00a0 | \u00a0 | 69,157 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,138 | \u00a0 | \u00a0 | \u00a0 | 61,468 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 7,933 | \u00a0 | \u00a0 | \u00a0 | 7,689 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,752 | \u00a0 | \u00a0 | \u00a0 | 13,297 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,096 | \u00a0 | \u00a0 | \u00a0 | 9,502 | \u00a0 |
| Wellness gross profit | \u00a0 | $ | 4,656 | \u00a0 | \u00a0 | $ | 3,795 | \u00a0 |
\u00a0
\nChannels of Cannabis revenue were as follows:
\n\u00a0
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,261 | \u00a0 | \u00a0 | $ | 6,142 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 57,235 | \u00a0 | \u00a0 | \u00a0 | 71,195 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 5,507 | \u00a0 | \u00a0 | \u00a0 | 5,295 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 12,191 | \u00a0 | \u00a0 | \u00a0 | 14,252 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (19,945 | ) | \u00a0 | \u00a0 | (26,551 | ) |
| Total | \u00a0 | $ | 61,249 | \u00a0 | \u00a0 | $ | 70,333 | \u00a0 |
\u00a0
\nIncluded in revenue from Canadian adult-use cannabis is \u00a0advisory services revenue for the three months ended August 31, 2024\u00a0from the previous HEXO commercial transaction agreements in place prior to its acquisition, compared to $1,500\u00a0in the prior period.
\n\u00a0
\n \n \nGeographic net revenue:
\n\u00a0
\n \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| USA | \u00a0 | $ | 63,880 | \u00a0 | \u00a0 | $ | 31,489 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 55,905 | \u00a0 | \u00a0 | \u00a0 | 62,032 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 77,672 | \u00a0 | \u00a0 | \u00a0 | 79,704 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 2,587 | \u00a0 | \u00a0 | \u00a0 | 3,724 | \u00a0 |
| Total | \u00a0 | $ | 200,044 | \u00a0 | \u00a0 | $ | 176,949 | \u00a0 |
\u00a0
\nGeographic capital assets:
\n\u00a0
\n \n| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| USA | \u00a0 | $ | 140,900 | \u00a0 | \u00a0 | $ | 141,314 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 312,432 | \u00a0 | \u00a0 | \u00a0 | 313,359 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 98,433 | \u00a0 | \u00a0 | \u00a0 | 99,921 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,371 | \u00a0 | \u00a0 | \u00a0 | 3,653 | \u00a0 |
| Total | \u00a0 | $ | 555,136 | \u00a0 | \u00a0 | $ | 558,247 | \u00a0 |
\u00a0
\nMajor customers are defined as customers that are materially significant\u00a0to the Company\u2019s annual revenues. For the three months ended August 31, 2024 and 2023, there were major customers representing a material contribution\u00a0to\u00a0our quarterly revenues.
\n "}]},{"name":"rpt:f-1205","factDimensions":{"xbrl:concept":"us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Beverage alcohol | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net beverage alcohol revenue | \u00a0 | $ | 55,972 | \u00a0 | \u00a0 | $ | 24,162 | \u00a0 |
| Beverage alcohol costs | \u00a0 | \u00a0 | 33,050 | \u00a0 | \u00a0 | \u00a0 | 11,266 | \u00a0 |
| Beverage alcohol gross profit | \u00a0 | \u00a0 | 22,922 | \u00a0 | \u00a0 | \u00a0 | 12,896 | \u00a0 |
| Cannabis | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Net cannabis revenue | \u00a0 | \u00a0 | 61,249 | \u00a0 | \u00a0 | \u00a0 | 70,333 | \u00a0 |
| Cannabis costs | \u00a0 | \u00a0 | 37,054 | \u00a0 | \u00a0 | \u00a0 | 50,517 | \u00a0 |
| Cannabis gross profit | \u00a0 | \u00a0 | 24,195 | \u00a0 | \u00a0 | \u00a0 | 19,816 | \u00a0 |
| Distribution | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Distribution revenue | \u00a0 | \u00a0 | 68,071 | \u00a0 | \u00a0 | \u00a0 | 69,157 | \u00a0 |
| Distribution costs | \u00a0 | \u00a0 | 60,138 | \u00a0 | \u00a0 | \u00a0 | 61,468 | \u00a0 |
| Distribution gross profit | \u00a0 | \u00a0 | 7,933 | \u00a0 | \u00a0 | \u00a0 | 7,689 | \u00a0 |
| Wellness | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 | \u00a0 |
| Wellness revenue | \u00a0 | \u00a0 | 14,752 | \u00a0 | \u00a0 | \u00a0 | 13,297 | \u00a0 |
| Wellness costs | \u00a0 | \u00a0 | 10,096 | \u00a0 | \u00a0 | \u00a0 | 9,502 | \u00a0 |
| Wellness gross profit | \u00a0 | $ | 4,656 | \u00a0 | \u00a0 | $ | 3,795 | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| Revenue from Canadian medical cannabis | \u00a0 | $ | 6,261 | \u00a0 | \u00a0 | $ | 6,142 | \u00a0 |
| Revenue from Canadian adult-use cannabis | \u00a0 | \u00a0 | 57,235 | \u00a0 | \u00a0 | \u00a0 | 71,195 | \u00a0 |
| Revenue from wholesale cannabis | \u00a0 | \u00a0 | 5,507 | \u00a0 | \u00a0 | \u00a0 | 5,295 | \u00a0 |
| Revenue from international cannabis | \u00a0 | \u00a0 | 12,191 | \u00a0 | \u00a0 | \u00a0 | 14,252 | \u00a0 |
| Less excise taxes | \u00a0 | \u00a0 | (19,945 | ) | \u00a0 | \u00a0 | (26,551 | ) |
| Total | \u00a0 | $ | 61,249 | \u00a0 | \u00a0 | $ | 70,333 | \u00a0 |
| \u00a0 | \u00a0 | For the three months ended | \u00a0 | |||||
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | August 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2023 | \u00a0 | ||
| USA | \u00a0 | $ | 63,880 | \u00a0 | \u00a0 | $ | 31,489 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 55,905 | \u00a0 | \u00a0 | \u00a0 | 62,032 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 77,672 | \u00a0 | \u00a0 | \u00a0 | 79,704 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 2,587 | \u00a0 | \u00a0 | \u00a0 | 3,724 | \u00a0 |
| Total | \u00a0 | $ | 200,044 | \u00a0 | \u00a0 | $ | 176,949 | \u00a0 |
| \u00a0 | \u00a0 | August 31, | \u00a0 | \u00a0 | May 31, | \u00a0 | ||
| \u00a0 | \u00a0 | 2024 | \u00a0 | \u00a0 | 2024 | \u00a0 | ||
| USA | \u00a0 | $ | 140,900 | \u00a0 | \u00a0 | $ | 141,314 | \u00a0 |
| Canada | \u00a0 | \u00a0 | 312,432 | \u00a0 | \u00a0 | \u00a0 | 313,359 | \u00a0 |
| EMEA | \u00a0 | \u00a0 | 98,433 | \u00a0 | \u00a0 | \u00a0 | 99,921 | \u00a0 |
| Rest of World | \u00a0 | \u00a0 | 3,371 | \u00a0 | \u00a0 | \u00a0 | 3,653 | \u00a0 |
| Total | \u00a0 | $ | 555,136 | \u00a0 | \u00a0 | $ | 558,247 | \u00a0 |
Note 27. Subsequent Events
\n\u00a0
\nEffective September 1, 2024,\u00a0the Company acquired four craft beer brands and breweries from Molson Coors Beverage Company\u00a0(\"Molson\") including Atwater Brewery,\u00a0Hop Valley Brewing Company,\u00a0Terrapin Beer Co., and\u00a0Revolver Brewing for a total purchase consideration of $23,079. This purchase price amount is\u00a0subject to certain customary post-closing working capital adjustments.
\n\u00a0
\nAs part of the Company's\u00a0ATM Program,\u00a0from September 1, 2024\u00a0to September\u00a010, 2024,\u00a0the Company issued an additional 10,132,247\u00a0shares generating gross proceeds of $17,059.\u00a0The Company paid $341\u00a0in commissions and other fees associated with these issuances generating\u00a0net proceeds of $16,718.
\n\u00a0
\nOn\u00a0 September 12, 2024,\u00a0the Company repurchased $7,500\u00a0of its TLRY\u00a027\u00a0Notes for cancellation by issuing 4,484,240\u00a0shares and paying $102\u00a0of cash to settle accrued interest. After cancellation, the outstanding principal balance of the TLRY\u00a027\u00a0Notes was $165,000.
\n\u00a0
\nOn September 17, 2024, the Company\u00a0entered into an assignment and assumption agreement\u00a0with Double Diamond Holdings Ltd. (\u201cDDH\u201d),\u00a0pursuant to which, among other things, Tilray acquired from DDH a promissory note in the amount of \u00a0(the \u201cNote\u201d) payable by Aphria Diamond Inc. (\u201cAphria Diamond\u201d). DDH is a joint venturer with Aphria Inc., Tilray\u2019s direct and wholly-owned subsidiary, in Aphria Diamond.\u00a0As consideration for the Note, Tilray issued\u00a013,217,588\u00a0shares of its common stock, par value $0.0001 per share\u00a0(the \u201cConsideration Shares\u201d), to DDH.
\n\u00a0
\n\u00a0
\n \n \n "}]},{"name":"rpt:f-1266","factDimensions":{"xbrl:concept":"us-gaap:BusinessCombinationConsiderationTransferred1","xbrl:period":"2024-09-01T00:00:00/2024-09-02T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:BusinessAcquisitionAxis":"tlry:AtwaterBreweryHopValleyBrewingCompanyTerrapinBeerCoAndRevolverBrewingMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"23079000","decimals":-3}]},{"name":"rpt:f-1267","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesEquityFinancing","xbrl:period":"2024-09-01T00:00:00/2024-09-11T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"10132247"}]},{"name":"rpt:f-1268","factDimensions":{"xbrl:concept":"us-gaap:ProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-09-01T00:00:00/2024-09-11T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"17059000","decimals":-3}]},{"name":"rpt:f-1269","factDimensions":{"xbrl:concept":"us-gaap:PaymentsOfStockIssuanceCosts","xbrl:period":"2024-09-01T00:00:00/2024-09-11T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"341000","decimals":-3}]},{"name":"rpt:f-1270","factDimensions":{"xbrl:concept":"tlry:NetProceedsFromIssuanceOfCommonStock","xbrl:period":"2024-09-01T00:00:00/2024-09-11T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember","us-gaap:SubsidiarySaleOfStockAxis":"tlry:AtthemarketProgramMember"},"factValues":[{"value":"16718000","decimals":-3}]},{"name":"rpt:f-1271","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfConvertibleDebt","xbrl:period":"2024-09-12T00:00:00/2024-09-13T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"7500000","decimals":-5}]},{"name":"rpt:f-1272","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesForTheRepaymentOfConvertibleDebt","xbrl:period":"2024-09-12T00:00:00/2024-09-13T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"4484240"}]},{"name":"rpt:f-1273","factDimensions":{"xbrl:concept":"us-gaap:InterestPaidNet","xbrl:period":"2024-09-12T00:00:00/2024-09-13T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"102000","decimals":-3}]},{"name":"rpt:f-1274","factDimensions":{"xbrl:concept":"us-gaap:RepaymentsOfConvertibleDebt","xbrl:period":"2024-09-13T00:00:00/2024-09-14T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD","us-gaap:DebtInstrumentAxis":"tlry:TLRY27Member","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"165000000","decimals":-6}]},{"name":"rpt:f-1275","factDimensions":{"xbrl:concept":"tlry:StockIssuedDuringPeriodSharesSettlementOfFinancingLiability","xbrl:period":"2024-09-17T00:00:00/2024-09-18T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"xbrla:shares","us-gaap:AssetAcquisitionAxis":"tlry:DoubleDiamondHoldingsLtdMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"13217588"}]},{"name":"rpt:f-1276","factDimensions":{"xbrl:concept":"us-gaap:CommonStockParOrStatedValuePerShare","xbrl:period":"2024-09-18T00:00:00","xbrl:entity":"cik:0001731348","xbrl:unit":"iso4217:USD/xbrla:shares","us-gaap:AssetAcquisitionAxis":"tlry:DoubleDiamondHoldingsLtdMember","us-gaap:SubsequentEventTypeAxis":"us-gaap:SubsequentEventMember"},"factValues":[{"value":"0.0001"}]},{"name":"rpt:f-1277","factDimensions":{"xbrl:concept":"ecd:MtrlTermsOfTrdArrTextBlock","xbrl:period":"2024-06-01T00:00:00/2024-09-01T00:00:00","xbrl:entity":"cik:0001731348"},"factValues":[{"value":" \n \n\u00a0
\nIn July 2024, the Board of Directors of the Company\u00a0approved fiscal year 2025 retention payments to the Company\u2019s senior executives (the \u201cExecutives\u201d) in the amounts set forth in the Company\u2019s Annual Report on Form 10-K, filed on July 30, 2024.\u00a0 The retention payments were made in August 2024 pursuant to a form of \u201cExecutive Retention Agreements\u201d entered into with each senior executive.
\n\u00a0
\nThe Company amended and restated\u00a0its form of \u201cExecutive Retention Agreements\u201d on August 15, 2024. Pursuant to the terms of amended\u00a0Executive Retention Agreement, such retention payments require continued employment for a period of time that was amended to commence on August 15, 2024, and continuing through the extended period of August 31, 2025 (the \u201cRepayment Period\u201d).\u00a0 If the Executive terminates employment without Good Reason or is terminated by the Company for Cause (both terms as defined in the Executive\u2019s employment agreements) prior to August 31, 2025, then such Executive must repay a pro-rated portion of the retention payment based on the number of days employed by the Company during the Repayment Period.\u00a0A copy of the form of amended and restated\u00a0Executive Retention Agreement is filed as an exhibit to this Form 10-Q.
\n\u00a0
\n \n \n "}]}]}}